<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ivabradine as adjuvant treatment for chronic heart failure - Benstoem, C - 2020 | Cochrane Library</title> <meta content="Ivabradine as adjuvant treatment for chronic heart failure - Benstoem, C - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013004.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ivabradine as adjuvant treatment for chronic heart failure - Benstoem, C - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013004.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013004.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Ivabradine as adjuvant treatment for chronic heart failure" name="citation_title"/> <meta content="Carina Benstoem" name="citation_author"/> <meta content="Medical Faculty, RWTH Aachen University" name="citation_author_institution"/> <meta content="cbenstoem@ukaachen.de" name="citation_author_email"/> <meta content="Christina Kalvelage" name="citation_author"/> <meta content="Medical Faculty, RWTH Aachen University" name="citation_author_institution"/> <meta content="Thomas Breuer" name="citation_author"/> <meta content="Medical Faculty, RWTH Aachen University" name="citation_author_institution"/> <meta content="Nicole Heussen" name="citation_author"/> <meta content="Gernot Marx" name="citation_author"/> <meta content="Medical Faculty, RWTH Aachen University" name="citation_author_institution"/> <meta content="Christian Stoppe" name="citation_author"/> <meta content="Medical Faculty, RWTH Aachen University" name="citation_author_institution"/> <meta content="Vincent Brandenburg" name="citation_author"/> <meta content="University Hospital RWTH Aachen" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013004.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013004.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013004.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013004.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Cardiovascular Agents [adverse effects, economics, *therapeutic use]; Cardiovascular Diseases [mortality]; Chemotherapy, Adjuvant; Chronic Disease; Exercise Tolerance [drug effects]; Heart Failure [*drug therapy, mortality]; Ivabradine [adverse effects, economics, *therapeutic use]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Stroke Volume" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013004.pub2&amp;doi=10.1002/14651858.CD013004.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6XSHdtL3";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013004\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013004\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","th","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013004.pub2",title:"Ivabradine as adjuvant treatment for chronic heart failure",firstPublishedDate:"Nov 4, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013004.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013004.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013004.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013004.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013004.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013004.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013004.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013004.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013004.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013004.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4364 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013004.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-sec-0018"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-sec-0019"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-sec-0095"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/appendices#CD013004-sec-0106"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/table_n/CD013004StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/table_n/CD013004StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ivabradine as adjuvant treatment for chronic heart failure</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#CD013004-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Carina Benstoem</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#CD013004-cr-0005">Christina Kalvelage</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#CD013004-cr-0006">Thomas Breuer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#CD013004-cr-0007">Nicole Heussen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#CD013004-cr-0008">Gernot Marx</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#CD013004-cr-0009">Christian Stoppe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information#CD013004-cr-0010">Vincent Brandenburg</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information/en#CD013004-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013004.pub2">https://doi.org/10.1002/14651858.CD013004.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013004-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013004-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013004-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013004-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013004-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD013004-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013004-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013004-abs-0001" lang="en"> <section id="CD013004-sec-0001"> <h3 class="title" id="CD013004-sec-0001">Background</h3> <p>Chronic heart failure is one of the most common medical conditions, affecting more than 23 million people worldwide. Despite established guideline‐based, multidrug pharmacotherapy, chronic heart failure is still the cause of frequent hospitalisation, and about 50% die within five years of diagnosis. </p> </section> <section id="CD013004-sec-0002"> <h3 class="title" id="CD013004-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of ivabradine in individuals with chronic heart failure. </p> </section> <section id="CD013004-sec-0003"> <h3 class="title" id="CD013004-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, and CPCI‐S Web of Science in March 2020. We also searched ClinicalTrials.gov and the WHO ICTRP. We checked reference lists of included studies. We did not apply any time or language restrictions. </p> </section> <section id="CD013004-sec-0004"> <h3 class="title" id="CD013004-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials in which adult participants diagnosed with chronic heart failure were randomly assigned to receive either ivabradine or placebo/usual care/no treatment. We distinguished between type of heart failure (heart failure with a reduced ejection fraction or heart failure with a preserved ejection fraction) as well as between duration of ivabradine treatment (short term (&lt; 6 months) or long term (≥ 6 months)). </p> </section> <section id="CD013004-sec-0005"> <h3 class="title" id="CD013004-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion, extracted data, and checked data for accuracy. We calculated risk ratios (RR) using a random‐effects model. We completed a comprehensive ’Risk of bias’ assessment for all studies. We contacted authors for missing data. Our primary endpoints were: mortality from cardiovascular causes; quality of life; time to first hospitalisation for heart failure during follow‐up; and number of days spent in hospital due to heart failure during follow‐up. Our secondary endpoints were: rate of serious adverse events; exercise capacity; and economic costs (narrative report). We assessed the certainty of the evidence applying the GRADE methodology. </p> </section> <section id="CD013004-sec-0006"> <h3 class="title" id="CD013004-sec-0006">Main results</h3> <p>We included 19 studies (76 reports) involving a total of 19,628 participants (mean age 60.76 years, 69% male). However, few studies contributed data to meta‐analyses due to inconsistency in trial design (type of heart failure) and outcome reporting and measurement. In general, risk of bias varied from low to high across the included studies, with insufficient detail provided to inform judgement in several cases. </p> <p>We were able to perform two meta‐analyses focusing on participants with heart failure with a reduced ejection fraction (HFrEF) and long‐term ivabradine treatment. There was evidence of no difference between ivabradine and placebo/usual care/no treatment for mortality from cardiovascular causes (RR 0.99, 95% confidence interval (CI) 0.88 to 1.11; 3 studies; 17,676 participants; I<sup>2</sup> = 33%; moderate‐certainty evidence). Furthermore, we found evidence of no difference in rate of serious adverse events amongst HFrEF participants randomised to receive long‐term ivabradine compared with those randomised to placebo, usual care, or no treatment (RR 0.96, 95% CI 0.92 to 1.00; 2 studies; 17,399 participants; I<sup>2</sup> = 12%; moderate‐certainty evidence). We were not able to perform meta‐analysis for all other outcomes, and have low confidence in the findings based on the individual studies. </p> </section> <section id="CD013004-sec-0007"> <h3 class="title" id="CD013004-sec-0007">Authors' conclusions</h3> <p>We found evidence of no difference in cardiovascular mortality and serious adverse events between long‐term treatment with ivabradine and placebo/usual care/no treatment in participants with heart failure with HFrEF. Nevertheless, due to indirectness (male predominance), the certainty of the available evidence is rated as moderate. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013004-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013004-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013004-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013004-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013004-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013004-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013004-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013004-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD013004-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013004-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013004-abs-0002" lang="en"> <h3>Ivabradine as adjuvant treatment for chronic heart failure</h3> <p><b>What is the aim of this review?</b> </p> <p>We investigated the effects of ivabradine (either as short‐term treatment (&lt; 6 months) or long‐term treatment (≥ 6 months) in people with heart failure and preserved (HFpEF, left ventricular ejection fraction is 50% or higher) or reduced ejection fraction (HFrEF, left ventricular ejection fraction is less than 40%). </p> <p><b>Key messages</b> </p> <p>We found that long‐term ivabradine has no effect on death from cardiovascular causes in people with HFrEF. We also found that there is no difference between long‐term ivabradine and placebo (dummy treatment), usual care, or no treatment in the rate of serious adverse events in people with HFrEF. </p> <p><b>What was studied in this review?</b> </p> <p>Heart failure is a common condition that occurs when the heart muscle is too weak to pump blood sufficiently to the body, which leads to symptoms like shortness of breath, tiredness, swelling of the legs, and a limited ability to exercise. About half of people who suffer from heart failure die within five years of diagnosis. Several medications are known to be effective in treating heart failure; however, we wanted to know if ivabradine could improve survival. Seven studies focused on short‐term treatment (&lt; 6 months) with ivabradine, and eleven studies focused on a long‐term treatment (≥ 6 months) with ivabradine. One study provided no information on duration of ivabradine administration. </p> <p><b>What are the main results of this review?</b> </p> <p>We found 19 randomised controlled trials (a type of study in which participants are assigned to one of two or more treatment groups using a random method) with a total of 19,628 participants investigating ivabradine. Eleven studies focused on HFrEF, three studies on HFpEF, and one study on heart failure with mid‐range ejection fraction (HFmrEF); no details were provided on heart failure in the remaining studies. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We searched for studies that had been published up to March 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013004-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013004-sec-0101"></div> <h3 class="title" id="CD013004-sec-0102">Implications for practice</h3> <section id="CD013004-sec-0102"> <p>Our found evidence suggests that long‐term treatment with ivabradine does not reduce mortality from cardiovascular causes or rate of serious adverse events in participants with HFrEF compared to placebo/usual care/no treatment. Nevertheless, due to significant differences across matching studies in trial design (type of heart failure, duration and dosage of ivabradine treatment), outcome reporting and measurement, the available evidence is uncertain. </p> </section> <h3 class="title" id="CD013004-sec-0103">Implications for research</h3> <section id="CD013004-sec-0103"> <p>Our results show the importance of a standardised approach regarding outcome definition and reporting in randomised controlled trials of similar scope (e.g. the implementation of minimum core outcome set) to assure the comparability of results across trials. In addition, we believe that clinical trials should follow guideline recommendations if the guideline management itself is not the focus of the investigation to assure the external applicability of research findings. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013004-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013004-sec-0008"></div> <div class="table" id="CD013004-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)<br/><b>Setting:</b> hospital or outpatient care<br/><b>Intervention:</b> long‐term treatment (≥ 6 months) with ivabradine<br/><b>Comparison:</b> placebo, usual care, or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality from cardiovascular causes (follow‐up range 19 to 23 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000 (93 to 117)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/>(0.88 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,676<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of no difference as the effect is close to 1 and the CI is narrow.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>: Treatment with ivabradine improved Kansas City Cardiomyopathy Questionnaire (KCCQ) by 1.8 (95% CI 0.30 to 3.24) for clinical summary score (CSS) and by 2.4 (95% CI 0.91 to 3.85) for overall summary score (OSS) (placebo‐corrected, P = 0.018 and P &lt; 0.001, respectively). </p> <p><a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>: Significant improvement (P = 0.004, no further details available) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2102</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first hospitalisation for heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of days spent in hospital due to heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000<br/>(296 to 321) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/>(0.92 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,399<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 additional RCTs (207 participants) could not be pooled.</p> <p><a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>: Author reported that no significant adverse effects on ivabradine therapy were noted at the end of 6 months; no further details are provided. </p> <p><a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>: Author reported that the addition of ivabradine to standard treatment promoted less fatal cardiovascular events; no further details are provided. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise capacity</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>: No significant improvement for ivabradine group in exercise duration (320 ± 130.6 s vs 311.79 ± 103.60 s) (P = 0.663) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Economic costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>All data are based on the SHIFT trial by <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>: </p> <p><a href="./references#CD013004-bbs2-0080" title="AdenaMA , HamannG , SindoneAP . Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart, Lung and Circulation2018;28(3):414-22.">Adena 2018</a>: Ivabradine is likely to be cost‐effective in Australia (cost per QALY = AUS 14,905). </p> <p><a href="./references#CD013004-bbs2-0086" title="BorerJS , DeedwaniaPC , KimJB , BoehmM . Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. American Journal of Cardiology2016;118(12):1948-53.">Borer 2016</a>: Ivabradine led to lower average annual treatment costs in the US (PMPM cost savings year 3: USD 0.04). </p> <p><a href="./references#CD013004-bbs2-0089" title="ChangCJ , ChuPH , FannCS . Cost effectiveness of ivabradine in chronic heart failure patients with heart rate above Bpm in Taiwan. Value Health2014;17:A488.">Chang 2014</a>: Ivabradine is likely to be cost‐effective in Taiwan (cost per QALY: GBP 14,832). </p> <p><a href="./references#CD013004-bbs2-0095" title="Fernandez de BobadillaJ , GonzalezFO , Lopez de SaE , Lopez-SendonJL . Cost-effectiveness analysis of ivabradine in heart failure with reduced left ventricular ejection fraction in Spain. Value in Health2014;17:A486.">Fernandez de Bobadilla 2014</a>: Ivabradine is cost‐effective in Spain (cost per QALY: EUR 17,488/cost per LYG: EUR 13,044). </p> <p><a href="./references#CD013004-bbs2-0099" title="GriffithsA , ParachaN , DaviesA , BranscombeN , CowieMR , SculpherM . The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective (Provisional abstract). Heart2014;100(13):1031-6.">Griffiths 2014</a>: Ivabradine is likely to be cost‐effective in the UK (cost per QALY: GBP 8498 (≥ 75 bpm)/GBP 13,764 (≥ 70 bpm). </p> <p><a href="./references#CD013004-bbs2-0105" title="KansalAR , CowieMR , KielhornA , KrotnevaS , TafazzoliA , ZhengY , et al. Cost-effectiveness of ivabradine for heart failure in the United States. Journal of the American Heart Association2016;5:06.">Kansal 2016</a>: Ivabradine is associated with cost savings in the USA (cost saving over 10‐year time horizon: USD 8594/QALY: 0.24/ICER per QALY: USD 24,920). </p> <p><a href="./references#CD013004-bbs2-0106" title="KourlabaG , ParissisJ , KaravidasA , BeletsiA , MilonasC , BranscombeN , et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Services Research2014;14:631.">Kourlaba 2014</a>: Ivabradine is a cost‐effective option in Greece (cumulative lifetime total cost per patient EUR 8665 vs EUR 5837/ICER per QALY: EUR 9986). </p> <p><a href="./references#CD013004-bbs2-0107" title="KrittayaphongR , YadeeJ , PermsuwanU . Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction. ClinicoEconomics and Outcomes Research2019;11:767-77.">Krittayaphong 2019</a>: The addition of ivabradine to standard treatment is a cost‐effective treatment strategy in HFrEF patients in Thailand with a heart rate ≥ 77 bpm (USD 6515.16/QALY). </p> <p><a href="./references#CD013004-bbs2-0119" title="PolistenaB , MaggioniA , OlivaF , SpandonaroF . Cost-effectiveness and budget impact of ivabradine in heart failure therapy (Provisional abstract). Giornale Italiano di Cardiologia2014;15:626-33.">Polistena 2014</a>: Results show social acceptability of ivabradine in Italy (cost per QALY: EUR 17,435/cost per LYG: EUR 15,557/HOS costs avoided: EUR 3420). </p> <p><a href="./references#CD013004-bbs2-0125" title="TaheriS , HeidariE , AivaziMA , Shams-BeyranvandM , VarmaghaniM . Cost-effectiveness analysis of Ivabradine in treatment of patients with heart failure in Iran. International Journal of Technology Assessment in Health Care2018;34(6):576–83.">Taheri 2018</a>: From an Iranian healthcare system, the analysis indicates that the clinical benefit of ivabradine can be achieved at a reasonable cost in eligible hear failure patients (cost per QALY: USD 5437). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6558</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the </p> <p><b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>bpm:</b> beats per minute; <b>CI:</b> confidence interval; <b>HFrEF:</b> heart failure with reduced ejection fraction; <b>HOS:</b> hospitalization; <b>ICER:</b> Incremental cost‐effectiveness ratio; <b>LYG:</b> life years gained;<b>PMPM:</b> per member per month; <b>QALY:</b> quality‐adjusted life year; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to indirectness (male predominance).<br/><sup>2</sup>Downgraded by one level due to risk of bias (allocation, blinding).<br/><sup>3</sup>Downgraded by one level due to imprecision (low number of participants).<br/><sup>4</sup>Downgraded by one level due to attrition bias (only around 30% of the overall trial participants contributed data). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013004-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)<br/><b>Setting:</b> hospital or outpatient care<br/><b>Intervention:</b> short‐term treatment (&lt; 6 months) with ivabradine<br/><b>Comparison:</b> placebo, usual care, or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality from cardiovascular causes (follow‐up range 19 to 23 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>: Minnesota Living with Heart Failure Questionnaire </p> <p>Significant improvement for ivabradine at 3 months vs baseline (37.5 + 1.9 vs 30.9 + 2.3) (P &lt; 0.001); no significant difference for control at 3 months vs baseline (31.2 + 2.6 vs 30.6 + 2.1) (P = n.s.) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first hospitalisation for heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of days spent in hospital due to heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>: Significant worsening of adverse events (heart failure, phosphenes, diarrhoea, nasopharyngitis): 54.8% (2.5 mg ivabradine); 64.3% (5 mg ivabradine) vs 29.3% (control) (P = 0.004) </p> <p><a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>: Noticeable side effects requiring the withdrawal of drugs were not observed. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>LOW<sup>1, 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise capacity</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>: Significant improvement for ivabradine group in exercise duration at 3 months (497 s vs 328 s) (P = 0.024) </p> <p><a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>: Significant improvement for ivabradine group in exercise duration at 90 days (495 ± 147 s vs 416 ± 128 s) (P &lt; 0.05) </p> <p><a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>: Significant improvement for ivabradine group in exercise duration at 3 months (28.2 ± 3.5 min vs 14.8 ± 2.5 min) (P &lt; 0.001) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Economic costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HFrEF:</b> heart failure with reduced ejection fraction;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision (low number of participants).<br/><sup>2</sup>Downgraded by one level due to risk of bias (blinding).<br/><sup>3</sup>Downgraded by one level due to publication bias (low number of studies reporting on this outcome). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013004-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with a diagnosis of chronic heart failure with a preserved ejection fraction (HFpEF)<br/><b>Setting:</b> hospital or outpatient care<br/><b>Intervention:</b> long‐term treatment (≥ 6 months) with ivabradine<br/><b>Comparison:</b> placebo, usual care, or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care with ivabradine compared to placebo, usual care, or no treatment in patients with HFpEF (long‐term treatment (≥ 6 months) with ivabradine)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality from cardiovascular causes</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>: 1 death from cardiovascular cause occurred in the ivabradine group (ischaemic stroke); no deaths occurred in the control group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a> </p> <p>No significant improvement (no further details available)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first hospitalisation for heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of days spent in hospital due to heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>: No significant difference in improvement (35.1% vs 25.0%) (P = 0.191) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise capacity</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>: No significant improvement for ivabradine group in 6‐minute walk test (change of last postbaseline value from baseline: +0.0 m vs +11.0 m) (P = 0.882) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Economic costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HFpEF:</b> heart failure with a preserved ejection fraction; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for imprecision (low number of participants).<br/><sup>2</sup>Downgraded by one level due to risk of bias (serious methodological limitations due to insufficient information on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013004-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with a diagnosis of chronic heart failure with a preserved ejection fraction (HFpEF)<br/><b>Setting:</b> hospital or outpatient care<br/><b>Intervention:</b> short‐term treatment (&lt; 6 months) with ivabradine<br/><b>Comparison:</b> placebo, usual care, or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality from cardiovascular causes (follow‐up range 19 to 23 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first hospitalisation for heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of days spent in hospital due to heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise capacity</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>: Significant improvement for ivabradine in exercise duration (baseline: 5.4 ± 2.1 min vs follow‐up at month 3: 6.9 ± 2.9 min) (P &lt; 0.05). No data for placebo group. </p> <p><a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>: Significant improvement for ivabradine group (baseline: 4.2 ± 1.8 metabolic equivalents vs follow‐up at day 7: 5.7 ± 1.9 metabolic equivalents) (P = 0.001). "No change in the control subjects." </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Economic costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HFpEF:</b> heart failure with a preserved ejection fraction; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to inconsistency (heterogeneity in parameters).<br/><sup>2</sup>Downgraded by one level due to imprecision (low number of participants). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013004-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013004-sec-0009"></div> <section id="CD013004-sec-0010"> <h3 class="title" id="CD013004-sec-0010">Description of the condition</h3> <section id="CD013004-sec-0011"> <h4 class="title">Definition of heart failure</h4> <p>Heart failure is defined as a complex clinical syndrome in which abnormal heart function results in, or increases the subsequent risk of, clinical symptoms and signs of reduced cardiac output, pulmonary or systemic congestion, or a combination, at rest or with stress (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). Individuals who have had heart failure for some time are said to have chronic heart failure (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). This subsequently leads to peripheral vasoconstriction, the increase of extracellular fluid volume accompanied by an increase in the end‐diastolic preload of the heart, and thus the inadequate adaptation of the cardiac output and inadequate systemic perfusion. Chronic heart failure, with its age‐dependent prevalence and incidence, is one of the most common medical conditions (<a href="./references#CD013004-bbs2-0122" title="RogerVL . Epidemiology of heart failure. Circulation Research2013;113:646–59.">Roger 2013</a>). </p> </section> <section id="CD013004-sec-0012"> <h4 class="title">Type and severity of heart failure</h4> <p>One commonly used method to classify the severity of heart failure is the New York Heart Association (NYHA) classification, which describes the functional status and symptoms of patients (<a href="#CD013004-tbl-0005">Table 1</a>) (<a href="./references#CD013004-bbs2-0093" title="EzekowitzJA , O'MearaEO , McDonaldMA , AbramsH , ChanM , DucharmeA . 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Canadian Journal of Cardiology2017;33:1342-433.">Ezekowitz 2017</a>; <a href="./references#CD013004-bbs2-0097" title="German Society for Cardiology. ESC Pocket Guidelines: Heart Failure [ESC Pocket Guidelines: Herzinsuffizienz]. leitlinien.dgk.org/files/2013_Pocket-Leitlinien_Herzinsuffizienz_Update_2012_Internet.pdf (accessed prior to 22 March 2018).">German Society for Cardiology 2013</a>; <a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). The terminology used to describe type and severity of heart failure is based on measurements of the left ventricular ejection fraction (LVEF) (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>): </p> <div class="table" id="CD013004-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">New York Heart Association (NYHA) classification</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Class</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other descriptor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms with ordinary activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild symptoms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms with less than ordinary<br/>activity </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate symptoms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms at rest or with any minimal<br/>activity </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe symptoms</p> </td> </tr> </tbody> </table> </div> <p> <ol id="CD013004-list-0001"> <li> <p>heart failure with a reduced ejection fraction (HFrEF) applies to patients with an LVEF less than 40%; </p> </li> <li> <p>heart failure with a preserved ejection fraction (HFpEF) applies to patients with an LVEF 50% or higher; and </p> </li> <li> <p>heart failure with a mid‐range ejection fraction (HFmrEF) applies to patients with an LVEF between 40% and 49%. </p> </li> </ol> </p> <p>Individuals with HFrEF and those with HFpEF have different clinical characteristics, are administered different treatment regimens, and might react differently to similar heart failure drugs (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). In HFpEF, also known as diastolic heart failure, the diagnosis is more complex than in HFrEF. Individuals with HFpEF generally do not have a dilated left ventricle; however, they often have an increase in thickness of the wall of the left ventricle and/or an increased left atrial size as a sign of increased filling pressures, therefore although the heart’s LVEF may still appear to be in the normal range, its pumping capacity is inadequate (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). In HFrEF, also known as systolic heart failure, the heart muscle is not able to contract adequately and therefore ejects oxygen‐rich blood only insufficiently into the body (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). </p> </section> <section id="CD013004-sec-0013"> <h4 class="title">Epidemiology of heart failure</h4> <p>Demographic changes and medical progress have contributed significantly to an increased prevalence of chronic heart failure, therefore heart failure is a first‐rate medical, social, and economic problem of our society. By 2013, more than 23 million individuals were diagnosed with heart failure worldwide (<a href="./references#CD013004-bbs2-0122" title="RogerVL . Epidemiology of heart failure. Circulation Research2013;113:646–59.">Roger 2013</a>). The prevalence of heart failure depends on the definition applied, but approximately 1% to 2% of the population in high‐income countries suffers from chronic heart failure, with the prevalence increasing to 10% or higher of the population aged over 70 years (<a href="./references#CD013004-bbs2-0108" title="LaribiS , AoubaA , NikolaouM , LassusJ , Cohen SolalA , PlaisanceP , et al. Trends in death attributed to heart failure over the past two decades in Europe. European Journal of Heart Failure2012;14:234–9.">Laribi 2012;</a><a href="./references#CD013004-bbs2-0114" title="MozaffarianD , BenjaminEJ , GoAS , ArnettDK , BlahaMJ , CushmanM , et al. Heart disease and stroke statistic. 2016 update. Circulation2016;133:e38–360.">Mozaffarian 2016)</a>. The lifetime risk of heart failure at age 55 years is 33% for men and 28% for women (<a href="./references#CD013004-bbs2-0085" title="BleuminkGS , KnetschAM , SturkenboomMCJM , StrausSMJM , HofmanA , DeckersJW , et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. European Heart Journal2004;25:1614–9.">Bleumink 2004</a>). Nearly three‐quarters (74%) of heart failure patients suffer from at least one accompanying morbidity, which is most likely to worsen patients’ overall health status (<a href="./references#CD013004-bbs2-0127" title="vanDeursenVM , UrsoR , LarocheC , DammanK , DahlströmU , TavazziL , et al. Co‐morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. European Journal of Heart Failure2014;16:103–11.">van Deursen 2014</a>). Over the last 50 years, age‐specific cardiovascular disease‐related mortality has fallen by about two‐thirds in industrialised countries. However, heart failure is a notable exception in this respect: in the USA, the rate of hospitalisation has increased steadily since 1975, up to 1.9 million cases per year (<a href="./references#CD013004-bbs2-0087" title="Centers for Disease Control and Prevention. Heart failure in the United States. www.cdc.gov/dhdsp/data_statistics/fact_sheets/docs/fs_heart_failure.pdf (accessed 20 June 2017).">CDC 2017</a>). Heart failure is the fourth most frequent cause of death in Germany today (<a href="./references#CD013004-bbs2-0124" title="Statistisches Bundesamt (Destatis). Todesursachen - Die 10 häufigsten Todesursachen insgesamt. www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Todesursachen/Tabellen/SterbefaelleInsgesamt.html (accessed prior to 22 March 2018).">Statistisches Bundesamt 2017</a>), and about half of people with heart failure die within five years of diagnosis (<a href="./references#CD013004-bbs2-0114" title="MozaffarianD , BenjaminEJ , GoAS , ArnettDK , BlahaMJ , CushmanM , et al. Heart disease and stroke statistic. 2016 update. Circulation2016;133:e38–360.">Mozaffarian 2016</a>). By 2030, the number of people with heart failure is expected to rise by 46% (<a href="./references#CD013004-bbs2-0084" title="BenjaminEJ , BlahaMJ , ChiuveSE , CushmanM , DasSR , DeoR , et al. Heart disease and stroke statistics - 2017 update: a report from the American Heart Association. Circulation2017;135:485-603.">Benjamin 2017</a>); reasons for this include an aging population and a growing number of heart attack survivors, who are at increased risk for heart failure. </p> </section> <section id="CD013004-sec-0014"> <h4 class="title">Therapy of heart failure</h4> <p>Therapy goals for chronic HFrEF are the improvement of individual quality of life, prolonged survival, a reduction of signs and symptoms, and the prevention of hospitalisation (<a href="./references#CD013004-bbs2-0097" title="German Society for Cardiology. ESC Pocket Guidelines: Heart Failure [ESC Pocket Guidelines: Herzinsuffizienz]. leitlinien.dgk.org/files/2013_Pocket-Leitlinien_Herzinsuffizienz_Update_2012_Internet.pdf (accessed prior to 22 March 2018).">German Society for Cardiology 2013</a>). In principle, therapeutic approaches (operative or medicinal) specific to the cause should be sought. According to the European Society of Cardiology (ESC) Clinical Practice Guideline on Acute and Chronic Heart Failure, optimal medical pharmacotherapy for chronic HFrEF involves the use of angiotensin‐converting‐enzyme inhibitors (ACE inhibitors) and beta‐blockers (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). Individuals with persistent symptoms should also receive a mineralocorticoid receptor antagonist (MRA) if the ejection fraction is 35% or less. The additional therapeutic value of selective MRAs like eplerenone has been shown by the reduction of morbidity and mortality in individuals after acute myocardial infarction, systolic heart failure, and left ventricular systolic dysfunction (<a href="./references#CD013004-bbs2-0118" title="PittB , WhiteH , NicolauJ , MartinezF , GheorghiadeM , AschermannM , et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Journal of the American College of Cardiology2005;46(3):425-31.">Pitt 2005</a>; <a href="./references#CD013004-bbs2-0130" title="ZannadF , McMurrayJJ , KrumH , vanVeldhuisenDJ , SwedbergK , ShiH , et al. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine2011;364(1):11-21.">Zannad 2011</a>). In summary, optimal medical pharmacotherapy for HFrEF includes ACE inhibitors plus beta‐blockers plus MRA. These therapy recommendations are in line with the recommendations made by the American Heart Association, <a href="./references#CD013004-bbs2-0129" title="YancyCW , JessuoM , BozkurtB , ButlerJ , Casey DE Jr, DraznerMH , et al. 2013 ACCF/AHA guideline for the management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013;128:240-327.">Yancy 2013</a>, and the Canadian Cardiovascular Society, <a href="./references#CD013004-bbs2-0093" title="EzekowitzJA , O'MearaEO , McDonaldMA , AbramsH , ChanM , DucharmeA . 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Canadian Journal of Cardiology2017;33:1342-433.">Ezekowitz 2017</a>. These drugs have a decisive influence on morbidity and mortality, as they have a positive effect on left ventricular function. This benefit appears to be partly due to a negative chronotropic effect (<a href="./references#CD013004-bbs2-0109" title="LechatP , HulotJS , EscolanoS , MalletA , LeizoroviczA , Werhlen-GrandjeanM , et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation2001;103:1428–33.">Lechat 2001</a>; <a href="./references#CD013004-bbs2-0112" title="McAlisterFA , WiebeN , EzekowitzJA , LeungAA , ArmstrongPW . Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Annals of Internal Medicine2009;150:784–94.">McAlister 2009</a>). However, even with the best medical treatment, the prognosis of HFrEF is still poor, especially in individuals with an increased resting pulse (70 to 75 beats per minute or higher). </p> <p>Heart failure adds significantly to the overall socioeconomic burden of disease, and will continue to do so in the future. In the USA, costs are quantified at USD 30,700 million each year, which includes the cost of healthcare services, medications to treat heart failure, and missed days of work (<a href="./references#CD013004-bbs2-0101" title="HeidenreichPA , TrogdonJG , KhavjouOA , ButlerJ , DracupK , EzekowitzMD , et al. Forecasting the future of cardiovascular disease in the United States. Circulation2011;123:933-44.">Heidenreich 2011</a>). The annual global economic cost of heart failure in 2012 was estimated at USD 108,000 million (<a href="./references#CD013004-bbs2-0090" title="CookC , ColeG , AsarisP , JabbourR , FrancisD . The annual global economic burden of heart failure. Heart2014;100:A28–9.">Cook 2014</a>). Heart failure costs are especially driven by repeated and prolonged hospitalisation, which accounts for 1% to 3% (approximately 1 million in total) of all USA and European hospital admissions per year (<a href="./references#CD013004-bbs2-0081" title="AmbrosyAP , FonarowGC , ButlerJ , ChioncelO , GreeneSJ , VaduganathanM , et al. The global health and economic burden of hospitalizations for heart failure. Journal of the American College of Cardiology2014;63:1123-33.">Ambrosy 2014</a>). Global registries on hospitalised heart failure show that the median length of stay ranges from 4 days to 20 days (<a href="./references#CD013004-bbs2-0081" title="AmbrosyAP , FonarowGC , ButlerJ , ChioncelO , GreeneSJ , VaduganathanM , et al. The global health and economic burden of hospitalizations for heart failure. Journal of the American College of Cardiology2014;63:1123-33.">Ambrosy 2014</a>). In addition, almost one out of four hospitalised individuals (24%) is rehospitalised for heart failure within the 30‐day postdischarge period, and nearly one out of two individuals (46%) is rehospitalised for heart failure within 60 days after discharge (<a href="./references#CD013004-bbs2-0116" title="O'ConnorCM , MillerAB , BlairJEA , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program. American Heart Journal2010;159:841-9.">O'Connor 2010</a>). </p> </section> </section> <section id="CD013004-sec-0015"> <h3 class="title" id="CD013004-sec-0015">Description of the intervention</h3> <p>Ivabradine, which is also known by the trade names Bradia (India), Coralan (Hong Kong, Singapore), Coraxan (Russia, Serbia), Corlanor (USA), Corlentor (Armenia, Spain, Italy, Romania), Ivabid (India), Lancora (Canada), Procoralan (worldwide), is used as an adjuvant oral medication for the symptomatic treatment of chronic heart failure. One film‐coated tablet contains 5 mg (equivalent to 5.390 mg) or 7.5 mg (equivalent to 8.085 mg) ivabradine as hydrochloride. Ivabradine is approved for the symptomatic treatment of chronic heart failure in NYHA class II to IV with systolic dysfunction, and in individuals with sinus rhythm with heart rate 75 beats per minute or higher, in combination with optimal medical pharmacotherapy (ACE inhibitors plus beta‐blockers plus MRA), or when beta‐blocker therapy is contraindicated or not tolerated. The European Medicines Agency states: "The usual recommended starting dose of ivabradine is 5 mg twice daily. After two weeks of treatment, the dose can be increased to 7.5 mg twice daily if the resting heart rate is persistently above 60 beats per minute, or decreased to 2.5 mg twice daily (one half 5 mg tablet twice daily) if the resting heart rate is persistently below 50 beats per minute, or in case of symptoms related to bradycardia, such as dizziness, fatigue, or hypotension. If the heart rate is between 50 and 60 beats per minute, the dose of 5 mg twice daily should be maintained. If, during treatment, the heart rate decreases and remains below 50 beats per minute at rest, or the patient experiences symptoms related to bradycardia, the dose must be titrated down to the next dose in persons receiving 7.5 mg twice daily or 5 mg twice daily. If the heart rate increases and remains above 60 beats per minute at rest, the dose can be titrated up to the next dose in persons receiving 2.5 mg twice daily or 5 mg twice daily. Treatment must be discontinued if heart rate remains below 50 beats per minute, or symptoms of bradycardia persist" (<a href="./references#CD013004-bbs2-0092" title="European Medicines Agency. Annex I Summary of product characteristics (of ivabradine). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000597/WC500043590.pdf (accessed prior to 22 March 2018).">EMA 2017</a>). These dosage and administration instructions are in line with the instructions of the US Food and Drug Administration (<a href="./references#CD013004-bbs2-0094" title="US Food and Drug Administration. CORLANOR(R) (ivabradine) Label. www.accessdata.fda.gov/drugsatfda_docs/label/2019/209964lbl.pdf (accessed prior to 24 June 2020).">FDA 2020</a>). </p> </section> <section id="CD013004-sec-0016"> <h3 class="title" id="CD013004-sec-0016">How the intervention might work</h3> <p>The cardiac effects of ivabradine are sinus node‐specific, and have no influence on the intra‐atrial, atrioventricular, or intraventricular stimulus conduction. Myocardial contractility and ventricular repolarisation remain unchanged. Ivabradine reduces the myocardial oxygen demand by reducing the heart rate, which makes the use of ivabradine interesting in individuals with chronic heart failure. Ivabradine is an active substance with heart rate‐lowering effects, which lead to a reduction of the effective arterial elastance (Ea) representing pulsatile and mean load of the left ventricle. The reduction of total afterload is mostly the result of a lower vascular pulsatile load. Ivabradine acts as an I<sub>f</sub>‐channel inhibitor to the heart, selectively inhibiting the I<sub>f</sub>‐ionic current, which controls the spontaneous diastolic depolarisation in the sinus node, thereby regulating the heart rate. As a result, the haemodynamic parameters remain constant, whilst at the same time the myocardial oxygen demand is reduced. The main pharmacodynamic property of ivabradine is a specific dose‐dependent reduction in heart rate. At the recommended dosage, the heart rate is lowered by about 10 beats per minute, both at rest and under load. Randomised controlled trials showed that when added to standard treatment, ivabradine significantly reduced the rate of a combined endpoint consisting of cardiovascular death and hospitalisation due to acute myocardial infarction, or hospitalisation due to new or worsening heart failure. It also reduced the incidence of death due to cardiac insufficiency, hospitalisation for any reason, or cardiovascular‐based hospitalisation (<a href="./references#CD013004-bbs2-0123" title="Servier Deutschland GmbH. Fachinformation Procoralan® . www.fachinfo.de/pdf/009422 (accessed prior to 22 March 2018).">Servier Deutschland GmbH 2016</a>). These aspects make the use of ivabradine very promising in individuals with chronic HFrEF. </p> </section> <section id="CD013004-sec-0017"> <h3 class="title" id="CD013004-sec-0017">Why it is important to do this review</h3> <p>Despite current intensive multidrug therapy, people with heart failure are frequently admitted to hospital. Even with the best medical treatment, the prognosis of heart failure remains poor. Individuals with NYHA stages II and III under therapy with ACE inhibitors have a one‐year mortality of 9% to 12%; those with end‐stage heart failure without therapy have a one‐year mortality of 52% (<a href="./references#CD013004-bbs2-0083" title="BauriedelG , SkowaschD , LuderitzB . Die chronische Herzinsuffizienz. Deutsches Ärzteblatt2005;102:1-12.">Bauriedel 2005</a>). The continuous development of therapeutic approaches for the treatment of the disease − in particular with regard to drugs with heart rate‐lowering properties − is of crucial importance. </p> <p>Although there are obvious promising characteristics, we want to highlight that the relevant national and international experts only rated the quality of the evidence as IIa (B) for the therapeutic use of ivabradine in corresponding guidelines (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). It is also important to note that to date, the effects of ivabradine have been based mainly on results from industry‐initiated studies (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>); the review of these results in science‐initiated studies is still pending. In summary, considering all aspects raised, it is anticipated that this Cochrane Review will have an impact on future clinical trials in this area. </p> <p>Two systematic reviews on this topic are available; however, both reviews have several limitations, with a significant impact on the conclusions (<a href="./references#CD013004-bbs2-0096" title="FoxK , KomajdaM , FordI , RobertsonM , BöhmM , BorerJS , et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal2013;34:2263-70.">Fox 2013</a>; <a href="./references#CD013004-bbs2-0113" title="MizzaciCC , PorfírioGJM , VilelaAT , GuillhenJCS , RieraR . Ivabradine as adjuvant treatment for chronic heart failure. International Journal of Cardiology2017;227:43-50.">Mizzaci 2017</a>). <a href="./references#CD013004-bbs2-0096" title="FoxK , KomajdaM , FordI , RobertsonM , BöhmM , BorerJS , et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal2013;34:2263-70.">Fox 2013</a> only considered two industry‐sponsored trials, one of which he was the principal investigator for (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>). <a href="./references#CD013004-bbs2-0113" title="MizzaciCC , PorfírioGJM , VilelaAT , GuillhenJCS , RieraR . Ivabradine as adjuvant treatment for chronic heart failure. International Journal of Cardiology2017;227:43-50.">Mizzaci 2017</a> was retracted in January 2017 on the request of several editors, as it contained numerous data inaccuracies (e.g. cited incorrect death rates), which made the conclusions unreliable (<a href="./references#CD013004-bbs2-0103" title="International Journal of Cardiology. Retraction notice to “Ivabradine as adjuvant treatment for chronic heart failure” [International Journal of Cardiology 2017; 227:43–50]. International Journal of Cardiology2017;247:55.">International Journal of Cardiology 2017</a>). There is a need to assess this evidence systematically and combine results across trials. This Cochrane Review will close this gap in research, providing the basis for future randomised controlled trials and clinical guidelines on the management of heart failure. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013004-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013004-sec-0018"></div> <p>To assess the effectiveness and safety of ivabradine in individuals with chronic heart failure. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013004-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013004-sec-0019"></div> <section id="CD013004-sec-0020"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013004-sec-0021"> <h4 class="title">Types of studies</h4> <p>We considered randomised clinical trials (RCTs) (individual, cross‐over, and cluster‐randomised trials) irrespective of publication type, publication status, publication date, and language for this review. For multi‐arm trials, we used only those treatment arms relevant to our review. </p> </section> <section id="CD013004-sec-0022"> <h4 class="title">Types of participants</h4> <p>We included adults (≥ 18 years of age) with a diagnosis of chronic heart failure. We contacted trialists if the age of participants was not stated clearly, or to obtain data for a subgroup of participants; the latter was not required in this review. If needed in future updates of the review, we will contact the study authors to ask for data concerning this subgroup. If no data for the corresponding subgroup can be provided, the publication will be excluded from quantitative analysis. </p> </section> <section id="CD013004-sec-0023"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing:</p> <p>Usual care with ivabradine compared to placebo, usual care, or no treatment</p> <p> <ol id="CD013004-list-0002"> <li> <p>usual care with placebo versus usual care with ivabradine; or</p> </li> <li> <p>usual care versus usual care with ivabradine; or</p> </li> <li> <p>no treatment versus usual care with ivabradine</p> </li> </ol> </p> <p>for the management of chronic heart failure. We combined the possible comparators into a single comparison. </p> <p>We distinguished between participants suffering from HFpEF, HFrEF, and HFmrEF, as well as duration of ivabradine treatment: </p> <p> <ol id="CD013004-list-0003"> <li> <p>participants with HFpEF with short‐term treatment (&lt; 6 months) with ivabradine;</p> </li> <li> <p>participants with HFpEF with long‐term treatment (≥ 6 months) with ivabradine;</p> </li> <li> <p>participants with HFrEF with short‐term treatment (&lt; 6 months) with ivabradine;</p> </li> <li> <p>participants with HFrEF with long‐term treatment (≥ 6 months) with ivabradine;</p> </li> <li> <p>participants with HFmrEF with short‐term treatment (&lt; 6 months) with ivabradine;</p> </li> <li> <p>participants with HFmrEF with long‐term treatment (≥ 6 months) with ivabradine.</p> </li> </ol> </p> <p>Studies also including participants with HFmrEF were assigned to HFpEF or HFrEF, depending on the main characteristics. </p> </section> <section id="CD013004-sec-0024"> <h4 class="title">Types of outcome measures</h4> <p>As no core outcome set for clinical studies investigating interventions in chronic heart failure participants is available, the list of outcomes chosen was based on outcome measures from studies potentially eligible for inclusion in our review that appeared to be most meaningful to patients, clinicians, and policymakers. </p> <section id="CD013004-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013004-list-0004"> <li> <p>Mortality from cardiovascular causes (as defined by trial authors).</p> </li> <li> <p>Quality of life (QoL) measured using validated scales, e.g. the Short Form Health Survey (SF‐36) (<a href="./references#CD013004-bbs2-0128" title="WareJEJ , SherbourneCD . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care1992;30(6):473-83.">Ware 1992</a>). </p> </li> <li> <p>Time to first hospitalisation for heart failure during follow‐up.</p> </li> <li> <p>Number of days spent in hospital due to heart failure during follow‐up.</p> </li> </ol> </p> </section> <section id="CD013004-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013004-list-0005"> <li> <p>Rate of serious adverse events (as defined by trial authors).</p> </li> <li> <p>Exercise capacity measured using validated scales, e.g. the 6‐minute walk test (6MWT) (<a href="./references#CD013004-bbs2-0082" title="American Thoracic Society, Board of Directors. ATS statement: guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine2002;166(1):111-7.">American Thoracic Society 2002</a>). </p> </li> <li> <p>Economic costs (narrative report).</p> </li> </ol> </p> <p>Reporting one or more of these outcomes in the trial was not an inclusion criteria for the review. Where a published report did not report one of these outcomes, we accessed the trial protocol and contacted the trial authors to ascertain whether the outcomes were measured but not reported. We included relevant trials that measured these outcomes but did not report the data at all, or reported data in an unuseable format, as part of the narrative. To maintain stringency we decided to report all outcomes in a 'Summary of findings' table, even though exercise capacity and economic costs were initially planned only for assessment and not for the 'Summary of findings' table. </p> </section> </section> </section> <section id="CD013004-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013004-sec-0028"> <h4 class="title">Electronic searches</h4> <p>We identified trials through systematic searches of the following bibliographic databases on 20 March 2020: </p> <p> <ol id="CD013004-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 3 of 12, 2020); </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 19 March 2020); </p> </li> <li> <p>Embase (Ovid, 1980 to 2020 week 11);</p> </li> <li> <p>Conference Proceedings Citation Index‐Science (CPCI‐S) Web of Science (Clarivate Analytics, 1990 to 20 March 2020). </p> </li> </ol> </p> <p>We adapted the preliminary search strategy for identifying trials in MEDLINE Ovid for use in the other databases (<a href="./appendices#CD013004-sec-0107">Appendix 1</a>). We applied the Cochrane sensitivity‐maximising randomised controlled trial filter to MEDLINE Ovid and adapted it for the other databases, except CENTRAL (<a href="./references#CD013004-bbs2-0110" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). </p> <p>We searched the US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) for ongoing or unpublished trials on 11 June 2020. </p> <p>We searched all databases from their inception to the present, and imposed no restriction on language of publication or publication status. </p> <p>We did not perform a separate search for adverse effects of interventions used for the treatment of chronic heart failure, considering adverse effects described in the included studies only. </p> <p>We identified economic evaluation studies through systematic searches of the following bibliographic databases on 20 March 2020: </p> <p> <ol id="CD013004-list-0007"> <li> <p>NHS Economic Evaluation Database (inception to 31 March 2015, when it stopped being updated); </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 2015 to 19 March 2020); </p> </li> <li> <p>Embase (Ovid, 2015 to 2020 week 11).</p> </li> </ol> </p> <p>We adapted the preliminary search strategy for identifying economic evaluation studies in MEDLINE Ovid for use in the other databases (<a href="./appendices#CD013004-sec-0108">Appendix 2</a>). We applied the NHS EED filter to MEDLINE Ovid and Embase Ovid (<a href="./references#CD013004-bbs2-0088" title="Centre for Reviews and Dissemination. NHS EED (NHS Economic Evaluation Database). www.crd.york.ac.uk/crdweb/ (accessed prior to 22 March 2018).">Centre for Reviews and Dissemination 2017</a>). </p> </section> <section id="CD013004-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all included studies and any relevant systematic reviews identified for additional references to trials. We also examined any relevant retraction statements and errata for included studies. We contacted authors for missing data and ongoing trials. </p> </section> </section> <section id="CD013004-sec-0030"> <h3 class="title" id="CD013004-sec-0030">Data collection and analysis</h3> <section id="CD013004-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Four review authors (CB, CK, TB, VB) independently screened titles and abstracts of all the studies identified as a result of the search, coding them as 'retrieve' (eligible, potentially eligible, or unclear), or 'do not retrieve'. We retrieved the full‐text study reports or publications. Four review authors (CB, CK, TB, VB) independently screened the full texts, identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. Any disagreements were resolved through discussion. We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete PRISMA flow diagrams (<a href="#CD013004-fig-0001">Figure 1</a>; <a href="#CD013004-fig-0002">Figure 2</a>) and <a href="./references#CD013004-sec-0118" title="">Characteristics of excluded studies</a> tables. </p> <div class="figure" id="CD013004-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for selection of randomised controlled trials." data-id="CD013004-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for selection of randomised controlled trials.</p> </div> </div> </div> <div class="figure" id="CD013004-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram for selection of economic evaluations." data-id="CD013004-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for selection of economic evaluations.</p> </div> </div> </div> </section> <section id="CD013004-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>We used a purposely developed data collection form for study characteristics and outcome data that had been piloted on one study in the review. Five review authors (CB, CK, TB, CS, VB) extracted the following study characteristics from the included studies. </p> <p> <ol id="CD013004-list-0008"> <li> <p>Methods: study design, total duration of study, details of any run‐in period, number of study centres and location, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: N randomised, N lost to follow‐up or withdrawn, N analysed, mean age, age range, gender, severity of condition (NYHA class), ejection fraction, pre‐existing heart‐disease, optimal medical pharmacotherapy according to guideline recommendations, inclusion and exclusion criteria, reported differences between intervention and comparison groups. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (CB, CK) independently extracted outcome data from the included studies to check each other's work. Any disagreements were resolved by consensus. Two review authors (CB, VB) transferred data into the Review Manager 5 file (<a href="./references#CD013004-bbs2-0121" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the data extraction form (CB or CK orTB). A second review author (CK) spot‐checked study characteristics for accuracy against the trial report. </p> <p>We also included a commentary on economic aspects of the use of ivabradine. This information is of special interest to policymakers and end‐users of this systematic review. We intended to address the economic burden of chronic heart failure, resource inputs, resource consequences, and issues of cost‐effectiveness. This narrative summary reports on the main characteristics and results of included economic studies, including resource use measures, cost, and cost‐effectiveness. We followed the recommendations in Chapter 15 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013004-bbs2-0102" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD013004-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Four review authors (CB, CK, TB, VB) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013004-bbs2-0102" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). Any disagreements were resolved by discussion. We assessed risk of bias according to the following domains. </p> <p> <ol id="CD013004-list-0009"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low, or unclear, and provided a quote from the study report, together with a justification for our judgement, in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed (<a href="#CD013004-fig-0003">Figure 3</a>; <a href="#CD013004-fig-0004">Figure 4</a>). Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <div class="figure" id="CD013004-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013004-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013004-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013004-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD013004-sec-0034"> <h4 class="title">Assessment of bias in conducting the systematic review</h4> <p>We conducted the review according to our published protocol, and reported any deviations from it in the <a href="#CD013004-sec-0115">Differences between protocol and review</a> section of the systematic review. </p> </section> <section id="CD013004-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as risk ratios (RR) with 95% confidence intervals (CI).</p> <p>We did not pool any continuous data, but we plan to use the mean difference with 95% CI for outcomes measured in the same way between trials and enter data as a scale with a consistent direction of effect where applicable in any future updates of this review. </p> <p>We reported the economic aspects of the use of ivabradine narratively.</p> </section> <section id="CD013004-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>No studies with a cross‐over design or cluster‐randomised trials were included in the review, so there were no unit of analysis issues. For multi‐arm studies, we analysed only those arms which met our inclusion criteria, but described any additional arms in the <a href="./references#CD013004-sec-0117" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD013004-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators to verify key study characteristics and to obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only). A detailed description of author feedback is provided in the <a href="./references#CD013004-sec-0117" title="">Characteristics of included studies</a> tables. </p> <section id="CD013004-sec-0038"> <h5 class="title">Dichotomous outcomes</h5> <p>We did not impute missing values for any outcomes in our primary analyses.</p> </section> <section id="CD013004-sec-0039"> <h5 class="title">Continuous data</h5> <p>We did not impute missing values for any outcomes in our primary analyses. If studies did not include standard deviations in their report, we calculated them using data from the trial if possible. </p> </section> </section> <section id="CD013004-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We started by inspecting forest plots visually to gauge likely levels of heterogeneity, and then used the I<sup>2</sup> statistic to measure heterogeneity amongst the trials in each analysis. When we identified substantial heterogeneity, we reported it and explored possible causes by prespecified subgroup analysis. We regarded heterogeneity as substantial if: </p> <p> <ol id="CD013004-list-0010"> <li> <p>the I<sup>2</sup> value was high (exceeding 30%); and </p> </li> <li> <p>there was inconsistency between trials in the direction or magnitude of effects (judged visually), or P &lt; 0.10 in the Chi<sup>2</sup> test for heterogeneity. </p> </li> </ol> </p> <p>We interpreted the I<sup>2</sup> taking into consideration the magnitude and direction of the treatment effects and the strength of the evidence for heterogeneity. </p> </section> <section id="CD013004-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We were not able to pool more than 10 trials, therefore we did not create a funnel plot to explore possible small‐study biases for the primary outcomes. We assessed reporting bias qualitatively, based on the characteristics of the included studies. </p> </section> <section id="CD013004-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses only when this was meaningful, that is if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. </p> <p>Given the clinical heterogeneity across trials on chronic heart failure patients and their differences in comorbidities and co‐medications, we used a random‐effects model to produce an overall summary of average treatment effect across trials. We treated the random‐effects summary as the average range of possible treatment effects. We presented results as the average treatment effect with its 95% CI, and the estimates of Tau<sup>2</sup> and I<sup>2</sup>. </p> </section> <section id="CD013004-sec-0043"> <h4 class="title">'Summary of findings' table</h4> <p>We created a 'Summary of findings' table for each of our four comparisons (<a href="./full#CD013004-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013004-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013004-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD013004-tbl-0004">summary of findings Table 4</a>). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of a body of evidence as it relates to the studies which contribute data to the meta‐analyses for the prespecified outcomes. We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013004-bbs2-0102" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), employing GRADEpro GDT software (<a href="./references#CD013004-bbs2-0098" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version (accessed 9 April 2018). Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). We justified all decisions to downgrade the certainty of evidence using footnotes, and made comments to aid the reader's understanding of the review where necessary. Two review authors (CB, VB) independently assessed the certaintyof the evidence; any disagreements were resolved by discussion or by involving a third review author (CK). We justified, documented, and incorporated our judgements into the reporting of results for each outcome. We extracted study data, formatted them into data tables, and prepared the 'Summary of findings' tables before writing the results and conclusions of our review. </p> </section> <section id="CD013004-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Due to heterogeneity in participant characteristics (e.g. mean age), differences in the underlying condition (HFpEF and HFrEF), and heterogeneity in outcome definition and reporting in the included studies, we were not able to perform subgroup analysis. </p> </section> <section id="CD013004-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>Based on the limited evidence available for this Cochrane Review, sensitivity analysis was not feasible. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013004-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013004-sec-0046"></div> <section id="CD013004-sec-0047"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD013004-sec-0117" title="">Characteristics of included studies</a>, <a href="./references#CD013004-sec-0118" title="">Characteristics of excluded studies</a>, and <a href="./references#CD013004-sec-0119" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD013004-sec-0048"> <h4 class="title">Results of the search</h4> <p>For the identification of RCTs, we performed the database searches in March 2020 and identified 752 citations with potential for inclusion after removal of duplicates. We excluded 499 citations during the initial screening of titles and abstracts. Overall, we assessed 231 full‐text references. A total of 149 references (reporting on 54 studies) failed to meet the inclusion criteria for this review. We assessed six references as ongoing studies (see <a href="./references#CD013004-sec-0119" title="">Characteristics of ongoing studies</a>). We included 19 studies (reported in 76 separate publications) in the review (the PRISMA study flow diagram for identification of RCTs is shown in <a href="#CD013004-fig-0001">Figure 1</a>). </p> <p>For the identification of economic evaluations, we performed the database searches in March 2020 and identified 35 publications with potential for inclusion after removal of duplicates. During screening, we excluded 25 publications that did not focus on the scope of our economic evaluation. We included 10 studies (reported in 10 publications) in the review (the PRISMA study flow diagram for identification of economic evaluations is shown in <a href="#CD013004-fig-0002">Figure 2</a>). </p> <p>We searched ClinicalTrials.gov and the WHO ICTRP to identify additional and ongoing trials that met the inclusion criteria of our systematic review. Details of our search strategy are provided in <a href="./appendices#CD013004-sec-0107">Appendix 1</a>. </p> </section> <section id="CD013004-sec-0049"> <h4 class="title">Included studies</h4> <p>We included 19 RCTs in the review (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). Detailed descriptions of the included studies are provided in the <a href="./references#CD013004-sec-0117" title="">Characteristics of included studies</a> tables. </p> <p>The included studies involved a total of 19,628 participants (mean age 60.76 years, 69% male) randomly assigned to receive either ivabradine or usual care/usual care plus placebo. Nine studies compared ivabradine to placebo and usual care (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>), whilst 10 studies compared ivabradine to usual care (<a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). All included trials used a standard parallel‐group design. Nine citations referred only to an abstract (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). We contacted the study authors (if contact details were available) to obtain further information on these studies, and when authors responded, we highlighted this in the corresponding <a href="./references#CD013004-sec-0117" title="">Characteristics of included studies</a> table. </p> <p>We identified six single‐centre studies, <a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>, and six multicentre studies, <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>; the number of centres ranged from 2 to 781, located around the world. This information was not available for the remaining studies. Most studies (N = 10) did not report details on funding (e.g. institutional funding or funding by an independent health department or research foundation). One study was funded by university and departmental means (<a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>); one was funded by the government (<a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>); and five studies received industrial funding/were funded by the pharmacological company that produced the investigational product (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>). </p> <p>The sample size ranged from 49 participants, in <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>, to 10,917 participants, in <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>. Most studies did not perform a power analysis. We noted a gender imbalance across all studies in favour of male participants (69%). </p> <p>Eleven studies focused on HFrEF (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>); three studies on HFpEF (<a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>); and one study on HFmrEF (<a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). The remaining studies provided no details on type of heart failure respectively on LVEF (<a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>). Summaries of study characteristics are shown for studies focusing on HFrEF in <a href="#CD013004-tbl-0006">Table 2</a> and for studies focusing on HFpEF in <a href="#CD013004-tbl-0007">Table 3</a>. There is no clear focus with respect to severity of heart failure in the included studies. NYHA classification included class 1 to 4 and various combinations of two or more NYHA classes. </p> <div class="table" id="CD013004-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Study characteristics of studies with HFrEF</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reference</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of centres</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ivabradine</b> </p> <p><b>[n]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo/SC</b> </p> <p><b>[n]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dosage</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration IP</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Timing outcomes</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ejection fraction [%]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Guideline adherence***</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="10" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term treatment (&lt; 6 months) with ivabradine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 0, 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EF &lt; 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, 30, 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EF &lt; 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with intolerance to BB were included; ACE/ARB and MRA were given.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 0, 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≤ 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (60.1%); ACE inhibitor (85%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 to 7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 0, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≤ 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (92.9%); ACE inhibitor (45.8%); ARB (26.8%); ACE inhibitor or ARB (70.6%); MRA (55.1%) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Long‐term treatment (</b> ≥<b>6 months) with ivabradine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 0, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF &lt; 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>781</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5479</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5438</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>~M 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, W 2, M 1, 3, 6, 12, 18, 24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF &lt; 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (83.5%); ACE inhibitor or ARB or both (89.5%); MRA (29.5%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y 3, 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y 3, 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF &lt; 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (85.7%); ACE inhibitor (96%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 mg/5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, 14, 28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF &lt; 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (79.7%); ACE inhibitor and/or ARB (85.2%); MRA (25.5%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>677</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3268</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3290</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, M 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≤ 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (89.5%); ACE inhibitor (78.5%); MRA (60.0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 to 7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every 2 M</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≤ 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACE inhibitor (48.9%); ARB (20.1%); ACE inhibitor and/or ARB (68.5%); MRA (77.6%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>∑ 9393</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>∑ 9337</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Reported only as abstract.<br/>**Initial dose 5 mg twice a day; after 2 weeks with a heart rate of 60/min or higher: 7.5 mg twice a day; if heart rate dropped below 50/min or other clinical symptoms of bradycardia: again 5 mg twice a day; if symptoms did not improve: ivabradine treatment stopped.<br/>***According to the European Society of Cardiology (ESC) Clinical Practice Guideline on Acute and Chronic Heart Failure (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). </p> <p>Abbreviations: ns = not specified; Y = year; M = month; W = week; D = day; ACE inhibitor = angiotensin‐converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BB = beta‐blockers; EF = ejection fraction; HFrEF = heart failure with reduced ejection fraction; IP = interventional product; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; SC = standard care </p> </div> </div> <div class="table" id="CD013004-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study characteristics of studies with HFpEF</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reference</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of centres</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ivabradine</b> </p> <p><b>[n]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo/SC</b> </p> <p><b>[n]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dosage</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration IP</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Timing outcomes</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ejection fraction [%]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Guideline adherence***</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Short‐term treatment (&lt; 6 months) with ivabradine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 0, 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EF ≥ 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, 7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≥ 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Long‐term treatment (</b> ≥<b>6 months) with ivabradine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine</p> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 mg/5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 0, 2, 4, 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≥ 45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (74.3%); ACE inhibitor or ARB (87.2%); MRA (29.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>∑ 178</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>∑ 173</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Reported only as abstract.<br/>**Initial dose 5 mg twice a day; after 2 weeks with a heart rate of 60/min or higher: 7.5 mg twice a day; if heart rate dropped below 50/min or other clinical symptoms of bradycardia: again 5 mg twice a day; if symptoms did not improve: ivabradine treatment stopped.<br/>***According to the European Society of Cardiology (ESC) Clinical Practice Guideline on Acute and Chronic Heart Failure (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). </p> <p>Abbreviations: ns = not specified; M = month; W = week; D = day; ACE inhibitor = angiotensin‐converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BB = beta‐blockers; EF = ejection fraction; IP = interventional prodcut; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; SC = standard care </p> </div> </div> <p>The included studies also drew a heterogeneous picture with regard to duration of ivabradine administration and dosage of ivabradine. Seven studies focused on short‐term treatment (&lt; 6 months) with ivabradine (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>), and 11 studies focused on long‐term treatment (≥ 6 months) with ivabradine (<a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). One study provided no information on duration of ivabradine administration (<a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>). The duration of interventional product (IP) administration varied significantly across studies, from one week, <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>, to 36 months, <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>. For the majority of included studies, dosage of ivabradine was based on the participant's heart rate, and ranged from 2.5 mg twice a day (often starting dose) to a maximum of 15 mg twice a day. </p> <p>Regarding adherence to guideline management of chronic heart failure, only four studies reported that all participants were treated with beta‐blockers and ACE inhibitors (<a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). In eight studies, part of the included participants received beta‐blockers (60.1% to 95.3%) and ACE inhibitors (45.8% to 96%), or MRA (29.3% to 77.6%) (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>). Of note, six studies provided no information on whether participants were treated with beta‐blockers, ACE inhibitors, angiotensin II receptor blockers (ARB), or MRA (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>). One study focused on participants with an intolerance to beta‐blockers (<a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>). </p> </section> <section id="CD013004-sec-0050"> <h4 class="title">Excluded studies</h4> <p>Overall, we excluded 54 studies during the full‐text screening process. Thirty‐three studies used a study design other than RCT; nine studies focused on a different study population; 11 studies assessed a different study intervention; one study ended prematurely; 27 references corresponded to unclear meta‐data from electronic databases due to missing information such as author or article name; six studies were not published at the time; and 68 studies were duplicates. For details, see <a href="./references#CD013004-sec-0118" title="">Characteristics of excluded studies</a> tables. Only the references of studies that might have been expected to meet the inclusion criteria but did not are listed. </p> </section> </section> <section id="CD013004-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias varied considerably across the included studies, and insufficient detail was provided to inform judgement in several cases (for an overview, see 'Risk of bias' graph in <a href="#CD013004-fig-0003">Figure 3</a> and 'Risk of bias’ summary table in <a href="#CD013004-fig-0004">Figure 4</a>). </p> <section id="CD013004-sec-0052"> <h4 class="title">Allocation</h4> <p>We judged seven studies as having a low risk of bias for random sequence generation (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>). Information was insufficient to permit a decision regarding 11 trials (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). We rated one study as having a high risk of bias (<a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>). </p> <p>We judged five studies as having a low risk of bias for allocation concealment (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>). Information was insufficient to permit a decision regarding 14 trials (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). No study was rated as having a high risk of bias. </p> </section> <section id="CD013004-sec-0053"> <h4 class="title">Blinding</h4> <p>We judged six studies as having low risk of performance bias, as participants and personnel were blinded to group allocation (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>). Nine studies did not use blinding and were rated as having a high risk of performance bias (<a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). Information was insufficient to permit a decision regarding four trials (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>). </p> <p>With regard to detection bias, only two studies reported blinding of outcome assessors (<a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>). For all other studies, information was insufficient to permit a decision. </p> </section> <section id="CD013004-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>We judged eight studies as having a low risk of attrition bias (<a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>). Information was insufficient to permit a decision regarding the remaining 11 trials. </p> </section> <section id="CD013004-sec-0055"> <h4 class="title">Selective reporting</h4> <p>We found trial registration protocols for <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>, <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>, and <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>. We did not find a trial registration protocol for the remaining studies to confirm whether all prespecified outcomes were reported in the publication. For seven studies (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>), the outcomes listed in the methods section were adequately reported in the results section. Information was insufficient to permit a decision regarding the remaining 12 trials. As we were not able to pool more than 10 trials, we did not include funnel plots in this review. </p> </section> <section id="CD013004-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>For most studies (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>), information was insufficient on which to base a judgement of low risk of bias. However, we rated three studies as at unclear risk of other potential sources of bias (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>). <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a> stated that "Representatives of the sponsor were non‐voting members of the study executive committee and were involved with the executive committee in the study design, interpretation of the data, and the writing of the report". The influence of the sponsor (Servier), who also funded the trial, resulted in a judgement of unclear risk of other potential sources of bias. With regard to <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>, the authors stated that "The data were collected and analysed and the first draft manuscript was written by the sponsor. It was fully reviewed and revised by the authors". In this study, as well as in <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>, the sponsor was Ono Pharmaceutical, who also funded the trial, resulting in a judgement of unclear risk of other potential sources of bias. We judged two studies to be at low risk of other potential sources of bias due to sufficient information concerning funding (no funding or internal funds) (<a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>). </p> </section> </section> <section id="CD013004-sec-0057"> <h3 class="title" id="CD013004-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD013004-tbl-0001"><b>Summary of findings 1</b> Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</a>; <a href="./full#CD013004-tbl-0002"><b>Summary of findings 2</b> Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine)</a>; <a href="./full#CD013004-tbl-0003"><b>Summary of findings 3</b> Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine)</a>; <a href="./full#CD013004-tbl-0004"><b>Summary of findings 4</b> Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine)</a> </p> <p>For the analyses of effects of interventions, we distinguished between type of heart failure (HFrEF and HFpEF) and duration of treatment with ivabradine (long‐term treatment (≥ 6 months) and short‐term treatment (&lt; 6 months)). <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a> (HFmrEF) reported no outcomes of interest. Four studies provided no details on type of heart failure (<a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0014" title="TatarchenkoIP , PozdnyakovaNV , BiryuchenkoMV , Kapelovich VYu, SekerkoSA , KupaevaRA . Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction. Terapevticheskii Arkhiv2008;80(9):40-4. ">Tatarchenko 2008</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>), thus we did not include these studies in our analysis. See 'Summary of findings' tables for each comparison (<a href="./full#CD013004-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013004-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013004-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD013004-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD013004-sec-0058"> <h4 class="title">1. Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine) </h4> <p>For this comparison, we assessed all trials that compared usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF, and in which ivabradine was given as long‐term treatment (≥ 6 months). Six studies met the inclusion criteria for this comparison (<a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>), five of which adhered partly to guideline recommendations for chronic heart failure management (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>). </p> <section id="CD013004-sec-0059"> <h5 class="title">Primary outcomes</h5> <section id="CD013004-sec-0060"> <h6 class="title">Mortality from cardiovascular causes</h6> <p>Three studies assessed mortality from cardiovascular causes (follow‐up range 19 months to 23 months) (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>). We found evidence of no difference (effect is close to 1, and the CI is narrow) between HFrEF participants randomised to receive ivabradine as a long‐term treatment compared with those randomised to placebo, usual care, or no treatment (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.88 to 1.11; 3 studies; 17,676 participants; I<sup>2</sup> = 33%; <a href="./references#CD013004-fig-0005" title="">Analysis 1.1</a>). </p> <p>Even though the CI on the forest plots overlap and all studies have a null effect, the effect estimates are going in opposite directions: <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a> favours placebo, whilst <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a> favours ivabradine, leading to an I<sup>2</sup> of 33%, which is suggestive of moderate heterogeneity. However, the mean heart rate at baseline as well as other demographics (age, sex, LVEF) and the dosage of ivabradine of <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a> are similar to <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>. The only main differences between <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a> and <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a> are the use of MRA (39.5% versus 60.0%) and the NYHA class (I‐III versus II‐IV). Participants with persistent symptoms should receive an MRA if the ejection fraction is 35% or less (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). The guideline adherence of <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a> was thus probably lower than that of <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>, which might have led to the tendency towards placebo. Additionally, the difference in NYHA classes is in line with the explanation of <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>, who argues that the tendency towards advantages of placebo are a result of insufficient reductions in heart rate. GRADE was assessed as moderate certainty due to indirectness (male predominance). </p> </section> <section id="CD013004-sec-0061"> <h6 class="title">Quality of life</h6> <p>Two studies reported on QoL (<a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>); the latter study was available as abstract only. QoL was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a> (n = 1944) reported that treatment with ivabradine improved KCCQ by 1.8 (95% CI 0.30 to 3.24) for clinical summary score (CSS) and by 2.4 (95% CI 0.91 to 3.85) for overall summary score (OSS) (placebo‐corrected, P = 0.018 and P &lt; 0.001, respectively). <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a> reported a significant improvement in QoL score six months after ivabradine treatment was added to optimal medical care (n = 158) (P = 0.004, no further details available). GRADE was assessed as low certainty due to risk of bias (blinding) and attrition bias. </p> </section> <section id="CD013004-sec-0062"> <h6 class="title">Time to first hospitalisation for heart failure during follow‐up</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> <section id="CD013004-sec-0063"> <h6 class="title">Number of days spent in hospital due to heart failure during follow‐up</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> </section> <section id="CD013004-sec-0064"> <h5 class="title">Secondary outcomes</h5> <section id="CD013004-sec-0065"> <h6 class="title">Rate of serious adverse events</h6> <p>Four studies included in this comparison reported on serious adverse events (<a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>; <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>), two of which provided data applicable for meta‐analysis (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>). <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a> did not define serious adverse events, but stated that no significant serious adverse effects on ivabradine therapy were noted at the end of six months. <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a> and <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a> did not define serious adverse events, thus it can be assumed that the standardised definition for clinical studies was applied (death, life‐threatening, hospitalisation, disability or permanent damage, congenital anomaly or birth defect). <a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a> reported on "serious adverse effects", and <a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a> reported on "cardiovascular events". We were able to report on the absolute number of participants experiencing at least one serious adverse event. We found no evidence of a difference in the rate of serious adverse events in HFrEF participants randomised to receive ivabradine as a long‐term treatment compared with those randomised to placebo, usual care, or no treatment with (RR 0.96, 95% CI 0.92 to 1.00; 2 studies; 17,399 participants; I<sup>2</sup> = 12%; <a href="./references#CD013004-fig-0006" title="">Analysis 1.2</a>). GRADE was assessed as moderate certainty due to indirectness (male predominance). </p> <p>For those studies that could not be pooled, it was reported that there were no significant adverse effects on ivabradine therapy noted at the end of six months (<a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>), and that the addition of ivabradine to standard treatment resulted in fewer fatal cardiovascular events (<a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>). </p> </section> <section id="CD013004-sec-0066"> <h6 class="title">Exercise capacity</h6> <p>Only one study reported on the total exercise duration after six months (<a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>), which was available as abstract only. The authors assessed "exercise duration (in seconds) by exercise test" and concluded that ivabradine failed to show significant improvement in exercise duration (320 ± 130.6 versus 311.79 ± 103.60, P = 0.663, 158 participants) when compared to standard of care. GRADE was downgraded two levels due to risk of bias (allocation, blinding) and imprecision (low number of participants) to low certainty. </p> </section> </section> </section> <section id="CD013004-sec-0067"> <h4 class="title">2. Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine) </h4> <p>For this comparison, we assessed all trials that compared usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF, and in which ivabradine was given as short‐term treatment (&lt; 6 months). Five studies met the inclusion criteria for this comparison (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>), of which only two trials adhered partly to guideline recommendations for chronic heart failure management (<a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>). </p> <section id="CD013004-sec-0068"> <h5 class="title">Primary outcomes</h5> <section id="CD013004-sec-0069"> <h6 class="title">Mortality from cardiovascular causes</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> <section id="CD013004-sec-0070"> <h6 class="title">Quality of life</h6> <p>Only one study reported on QoL after three months using the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (<a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>). The authors concluded that ivabradine showed a significant improvement in QoL score at three months versus baseline (37.5 ± 1.9 versus 30.9 + 2.3; P &lt; 0.001; 60 participants) when compared to standard of care at three months versus baseline (31.2 + 2.6 versus 30.6 + 2.1) (P value not specified). Nevertheless, this 'significant improvement' shows no clinically meaningful difference, as the MLHFQ is of limited clinical relevance. GRADE was downgraded one level for imprecision (low number of participants) and one level for risk of bias (blinding) to low certainty. </p> </section> <section id="CD013004-sec-0071"> <h6 class="title">Time to first hospitalisation for heart failure during follow‐up</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> <section id="CD013004-sec-0072"> <h6 class="title">Number of days spent in hospital due to heart failure during follow‐up</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> </section> <section id="CD013004-sec-0073"> <h5 class="title">Secondary outcomes</h5> <section id="CD013004-sec-0074"> <h6 class="title">Rate of serious adverse events</h6> <p>Two studies reported on serious adverse events (<a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>). <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a> reported that the incidence of adverse events (heart failure, phosphenes, diarrhoea, nasopharyngitis) was 54.8% in the 2.5 mg ivabradine group and 64.3% in the 5 mg ivabradine group, which was significantly higher than in the placebo group (29.3%) (P = 0.004, 125 participants). Even though <a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a> defines these events as adverse events and not as serious adverse events, we decided to document these results due to the strong similarity with the definitions of the other publications. <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a> (n = 145) reported that noticeable side effects requiring the withdrawal of drugs were not observed. GRADE was downgraded one level for imprecision (low number of participants) and one level for publication bias (low number of studies reporting on this outcome) to low certainty. </p> </section> <section id="CD013004-sec-0075"> <h6 class="title">Exercise capacity</h6> <p>Three studies reported on exercise capacity (<a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>; <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>). <a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a> measured mean exercise duration in seconds after three months; <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a> measured exercise capacity in total duration in seconds at day 90; and <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a> reported on exercise duration at submaximal load in minutes as well as maximal workload in watt. Pooling of data was not feasible due to the missing standard deviation of <a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a> and the differences in the exercise test protocol between <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a> (Bruce protocol) and <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a> (specific protocol); the latter led to exercise duration differences of more than twice as large values, thus we decided not to pool those data. <a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a> reported that after 12 weeks of ivabradine therapy, the mean exercise duration time increased significantly from 328 seconds to 497 seconds (P = 0.024, 100 participants). <a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a> noted significant improvement at 90 days (495 ± 147 s versus 416 ± 128 s) in exercise time or maximal workload (P &lt; 0.05, 145 participants). <a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a> reported that the exercise capacity increased from 14.8 ± 2.5 min to 28.2 ± 3.5 min in the ivabradine group when compared to placebo (P &lt; 0.001, 60 participants). GRADE was downgraded two levels due to risk of bias (blinding) and imprecision (low number of participants) to low certainty. </p> </section> </section> </section> <section id="CD013004-sec-0076"> <h4 class="title">3. Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine) </h4> <p>For this comparison, we assessed all trials that compared usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF, in which ivabradine was given as long‐term treatment (≥ 6 months). Only one study met the inclusion criteria for this comparison. As <a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a> included participants with an LVEF ≥ 45%, it could also have been assigned to the HFmrEF group. However, since they reported that mean LVEF at baseline was 60.5%, we decided to analyse the results of this study in the group of participants with HFpEF. </p> <section id="CD013004-sec-0077"> <h5 class="title">Primary outcomes</h5> <section id="CD013004-sec-0078"> <h6 class="title">Mortality from cardiovascular causes</h6> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a> reported on mortality from cardiovascular causes. One death from cardiovascular cause occurred in the ivabradine group (ischaemic stroke), and no deaths occurred in the control group. GRADE was downgraded one level for imprecision (low number of participants) and by one level due to risk of bias (serious methodological limitations due to insufficient information on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting) to low certainty. </p> </section> <section id="CD013004-sec-0079"> <h6 class="title">Quality of life</h6> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a> reported on QoL at baseline and after two, four, and eight months using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Findings on the KCCQ changed minimally in both treatment groups. GRADE was downgraded one level for imprecision (low number of participants) and by one level due to risk of bias (serious methodological limitations due to insufficient information on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting) to low certainty. </p> </section> <section id="CD013004-sec-0080"> <h6 class="title">Time to first hospitalisation for heart failure during follow‐up</h6> <p>This outcome was not reported in the study that met the inclusion criteria for this comparison. </p> </section> <section id="CD013004-sec-0081"> <h6 class="title">Number of days spent in hospital due to heart failure during follow‐up</h6> <p>This outcome was not reported in the study that met the inclusion criteria for this comparison. </p> </section> </section> <section id="CD013004-sec-0082"> <h5 class="title">Secondary outcomes</h5> <section id="CD013004-sec-0083"> <h6 class="title">Rate of serious adverse events</h6> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a> reported on serious adverse events, but did not define serious adverse events, thus it can be assumed that the standardised definition for clinical studies was applied (death, life‐threatening, hospitalisation, disability or permanent damage, congenital anomaly or birth defect). The authors reported that the incidence of serious adverse events was 35.1% in the ivabradine group and 25.0% in the placebo group (P = 0.191), showing no statistically significant differences between groups. GRADE was downgraded one level for imprecision (low number of participants) and one level due to risk of bias (serious methodological limitations due to insufficient information on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting) to low certainty. </p> </section> <section id="CD013004-sec-0084"> <h6 class="title">Exercise capacity</h6> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a> reported on exercise capacity by comparing the results of a 6‐minute walk test (6MWT) at baseline and after two, six, and eight months. The distance covered during the 6MWT did not change in the active group (P = 0.882). GRADE was downgraded one level for imprecision (low number of participants) and one level due to risk of bias (serious methodological limitations due to insufficient information on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting) to low certainty. </p> </section> </section> </section> <section id="CD013004-sec-0085"> <h4 class="title">4. Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine) </h4> <p>For this comparison, we assessed all trials that compared usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF, in which ivabradine was given as short‐term treatment (&lt; 6 months). Two studies met the inclusion criteria for this comparison (<a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>). For both studies, we had insufficient information to judge adherence to guideline recommendations for chronic heart failure management. </p> <section id="CD013004-sec-0086"> <h5 class="title">Primary outcomes</h5> <section id="CD013004-sec-0087"> <h6 class="title">Mortality from cardiovascular causes</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> <section id="CD013004-sec-0088"> <h6 class="title">Quality of life</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> <section id="CD013004-sec-0089"> <h6 class="title">Time to first hospitalisation for heart failure during follow‐up</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> <section id="CD013004-sec-0090"> <h6 class="title">Number of days spent in hospital due to heart failure during follow‐up</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> </section> <section id="CD013004-sec-0091"> <h5 class="title">Secondary outcomes</h5> <section id="CD013004-sec-0092"> <h6 class="title">Rate of serious adverse events</h6> <p>This outcome was not reported in studies that met the inclusion criteria for this comparison. </p> </section> <section id="CD013004-sec-0093"> <h6 class="title">Exercise capacity</h6> <p>Both studies included in this comparison focused on exercise capacity (<a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>; <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>); however, the definition and measurement tool were too heterogenous to allow pooling. <a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a> documented significant improvement in exercise duration (baseline: 5.4 ± 2.1 min versus follow‐up at month 3: 6.9 ± 2.9 min) (P &lt; 0.05). No data were provided for the placebo group. <a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a> reported significant improvement in metabolic equivalents (METs) (baseline: 4.2 ± 1.8 versus follow‐up at day 7: 5.7 ± 1.9 METs) (P = 0.001), and "no change in the control subjects". GRADE was downgraded two levels for inconsistency (heterogeneity in parameters) and for imprecision (low number of participants) to low certainty. </p> </section> </section> </section> <section id="CD013004-sec-0094"> <h4 class="title">Economic evaluation</h4> <p>Database searches in March 2020 resulted in 35 citations, 25 of which were excluded as they were reviews or duplicates and thus missing the focus on the scope of our economic evaluation. A total of 10 studies were thus included in this narrative summary reporting on economic aspects of chronic heart failure therapy with ivabradine (<a href="./references#CD013004-bbs2-0080" title="AdenaMA , HamannG , SindoneAP . Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart, Lung and Circulation2018;28(3):414-22.">Adena 2018</a>; <a href="./references#CD013004-bbs2-0086" title="BorerJS , DeedwaniaPC , KimJB , BoehmM . Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. American Journal of Cardiology2016;118(12):1948-53.">Borer 2016</a>; <a href="./references#CD013004-bbs2-0089" title="ChangCJ , ChuPH , FannCS . Cost effectiveness of ivabradine in chronic heart failure patients with heart rate above Bpm in Taiwan. Value Health2014;17:A488.">Chang 2014</a>; <a href="./references#CD013004-bbs2-0095" title="Fernandez de BobadillaJ , GonzalezFO , Lopez de SaE , Lopez-SendonJL . Cost-effectiveness analysis of ivabradine in heart failure with reduced left ventricular ejection fraction in Spain. Value in Health2014;17:A486.">Fernandez de Bobadilla 2014</a>; <a href="./references#CD013004-bbs2-0099" title="GriffithsA , ParachaN , DaviesA , BranscombeN , CowieMR , SculpherM . The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective (Provisional abstract). Heart2014;100(13):1031-6.">Griffiths 2014</a>; <a href="./references#CD013004-bbs2-0105" title="KansalAR , CowieMR , KielhornA , KrotnevaS , TafazzoliA , ZhengY , et al. Cost-effectiveness of ivabradine for heart failure in the United States. Journal of the American Heart Association2016;5:06.">Kansal 2016</a>; <a href="./references#CD013004-bbs2-0106" title="KourlabaG , ParissisJ , KaravidasA , BeletsiA , MilonasC , BranscombeN , et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Services Research2014;14:631.">Kourlaba 2014</a>; <a href="./references#CD013004-bbs2-0107" title="KrittayaphongR , YadeeJ , PermsuwanU . Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction. ClinicoEconomics and Outcomes Research2019;11:767-77.">Krittayaphong 2019</a>; <a href="./references#CD013004-bbs2-0119" title="PolistenaB , MaggioniA , OlivaF , SpandonaroF . Cost-effectiveness and budget impact of ivabradine in heart failure therapy (Provisional abstract). Giornale Italiano di Cardiologia2014;15:626-33.">Polistena 2014</a>; <a href="./references#CD013004-bbs2-0125" title="TaheriS , HeidariE , AivaziMA , Shams-BeyranvandM , VarmaghaniM . Cost-effectiveness analysis of Ivabradine in treatment of patients with heart failure in Iran. International Journal of Technology Assessment in Health Care2018;34(6):576–83.">Taheri 2018</a>). The studies were published between 2014 and 2019, and two studies were available as abstracts only (<a href="./references#CD013004-bbs2-0089" title="ChangCJ , ChuPH , FannCS . Cost effectiveness of ivabradine in chronic heart failure patients with heart rate above Bpm in Taiwan. Value Health2014;17:A488.">Chang 2014</a>; <a href="./references#CD013004-bbs2-0095" title="Fernandez de BobadillaJ , GonzalezFO , Lopez de SaE , Lopez-SendonJL . Cost-effectiveness analysis of ivabradine in heart failure with reduced left ventricular ejection fraction in Spain. Value in Health2014;17:A486.">Fernandez de Bobadilla 2014</a>). <a href="./references#CD013004-bbs2-0119" title="PolistenaB , MaggioniA , OlivaF , SpandonaroF . Cost-effectiveness and budget impact of ivabradine in heart failure therapy (Provisional abstract). Giornale Italiano di Cardiologia2014;15:626-33.">Polistena 2014</a> was published in Italian only; the abstract was available in English. Notably, all analyses were based on data from the SHIFT trial reporting long‐term treatment with ivabradine in participants with HFrEF (<a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>). Based on the reports, we want to acknowledge that all studies adapted the predeveloped Markov model to a certain population, which was purposely developed for "submission to national regulatory bodies" (<a href="./references#CD013004-bbs2-0119" title="PolistenaB , MaggioniA , OlivaF , SpandonaroF . Cost-effectiveness and budget impact of ivabradine in heart failure therapy (Provisional abstract). Giornale Italiano di Cardiologia2014;15:626-33.">Polistena 2014</a>). Studies used the Markov model to assess the cost‐effectiveness of ivabradine on top of standard care in heart failure therapy and compared it to data from Australia (<a href="./references#CD013004-bbs2-0080" title="AdenaMA , HamannG , SindoneAP . Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart, Lung and Circulation2018;28(3):414-22.">Adena 2018</a>), the USA (<a href="./references#CD013004-bbs2-0086" title="BorerJS , DeedwaniaPC , KimJB , BoehmM . Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. American Journal of Cardiology2016;118(12):1948-53.">Borer 2016</a>; <a href="./references#CD013004-bbs2-0105" title="KansalAR , CowieMR , KielhornA , KrotnevaS , TafazzoliA , ZhengY , et al. Cost-effectiveness of ivabradine for heart failure in the United States. Journal of the American Heart Association2016;5:06.">Kansal 2016</a>), Taiwan (<a href="./references#CD013004-bbs2-0089" title="ChangCJ , ChuPH , FannCS . Cost effectiveness of ivabradine in chronic heart failure patients with heart rate above Bpm in Taiwan. Value Health2014;17:A488.">Chang 2014</a>), Spain (<a href="./references#CD013004-bbs2-0095" title="Fernandez de BobadillaJ , GonzalezFO , Lopez de SaE , Lopez-SendonJL . Cost-effectiveness analysis of ivabradine in heart failure with reduced left ventricular ejection fraction in Spain. Value in Health2014;17:A486.">Fernandez de Bobadilla 2014</a>), the UK (<a href="./references#CD013004-bbs2-0099" title="GriffithsA , ParachaN , DaviesA , BranscombeN , CowieMR , SculpherM . The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective (Provisional abstract). Heart2014;100(13):1031-6.">Griffiths 2014</a>), Greece (<a href="./references#CD013004-bbs2-0106" title="KourlabaG , ParissisJ , KaravidasA , BeletsiA , MilonasC , BranscombeN , et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Services Research2014;14:631.">Kourlaba 2014</a>), Iran (<a href="./references#CD013004-bbs2-0125" title="TaheriS , HeidariE , AivaziMA , Shams-BeyranvandM , VarmaghaniM . Cost-effectiveness analysis of Ivabradine in treatment of patients with heart failure in Iran. International Journal of Technology Assessment in Health Care2018;34(6):576–83.">Taheri 2018</a>), Thailand (<a href="./references#CD013004-bbs2-0107" title="KrittayaphongR , YadeeJ , PermsuwanU . Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction. ClinicoEconomics and Outcomes Research2019;11:767-77.">Krittayaphong 2019</a>), and Italy (<a href="./references#CD013004-bbs2-0119" title="PolistenaB , MaggioniA , OlivaF , SpandonaroF . Cost-effectiveness and budget impact of ivabradine in heart failure therapy (Provisional abstract). Giornale Italiano di Cardiologia2014;15:626-33.">Polistena 2014</a>). </p> <p>For the studies available as abstracts only, no information on funding or conflict of interests was provided. Five studies reported that they were funded either by Servier Laboratories or by Amgen; both companies are known for their close collaboration with the authors (see <a href="#CD013004-sec-0056">Other potential sources of bias</a>) (<a href="./references#CD013004-bbs2-0080" title="AdenaMA , HamannG , SindoneAP . Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart, Lung and Circulation2018;28(3):414-22.">Adena 2018</a>; <a href="./references#CD013004-bbs2-0086" title="BorerJS , DeedwaniaPC , KimJB , BoehmM . Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. American Journal of Cardiology2016;118(12):1948-53.">Borer 2016</a>; <a href="./references#CD013004-bbs2-0099" title="GriffithsA , ParachaN , DaviesA , BranscombeN , CowieMR , SculpherM . The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective (Provisional abstract). Heart2014;100(13):1031-6.">Griffiths 2014</a>; <a href="./references#CD013004-bbs2-0105" title="KansalAR , CowieMR , KielhornA , KrotnevaS , TafazzoliA , ZhengY , et al. Cost-effectiveness of ivabradine for heart failure in the United States. Journal of the American Heart Association2016;5:06.">Kansal 2016</a>; <a href="./references#CD013004-bbs2-0106" title="KourlabaG , ParissisJ , KaravidasA , BeletsiA , MilonasC , BranscombeN , et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Services Research2014;14:631.">Kourlaba 2014</a>). Multiple authors of the five publications are employees of Servier or Amgen. In addition, various authors have accepted funds from companies (received honoraria, speaker fees, consultancy fees) or are members of advisory boards or have appeared on expert panels, for example for Servier. </p> <p>Nevertheless, we assessed quality according to quality checklist of <a href="./references#CD013004-bbs2-0091" title="DrummondMF , JeffersonTO . British Medical Journal Checklist for authors and peer reviewers of economic submissions. BMJ1996;313(7052):275-83.">Drummond 1996</a> as good for all included studies that were present as full text. GRADE was downgraded one level to moderate due to risk of bias (influence of the sponsor) (<a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>). </p> <p>Most of the studies focused on the economic question of the cost‐effectiveness of ivabradine, including its impact on survival and quality of life from a general healthcare analytic viewpoint (<a href="./references#CD013004-bbs2-0080" title="AdenaMA , HamannG , SindoneAP . Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart, Lung and Circulation2018;28(3):414-22.">Adena 2018</a>; <a href="./references#CD013004-bbs2-0089" title="ChangCJ , ChuPH , FannCS . Cost effectiveness of ivabradine in chronic heart failure patients with heart rate above Bpm in Taiwan. Value Health2014;17:A488.">Chang 2014</a>; <a href="./references#CD013004-bbs2-0095" title="Fernandez de BobadillaJ , GonzalezFO , Lopez de SaE , Lopez-SendonJL . Cost-effectiveness analysis of ivabradine in heart failure with reduced left ventricular ejection fraction in Spain. Value in Health2014;17:A486.">Fernandez de Bobadilla 2014</a>; <a href="./references#CD013004-bbs2-0099" title="GriffithsA , ParachaN , DaviesA , BranscombeN , CowieMR , SculpherM . The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective (Provisional abstract). Heart2014;100(13):1031-6.">Griffiths 2014</a>; <a href="./references#CD013004-bbs2-0106" title="KourlabaG , ParissisJ , KaravidasA , BeletsiA , MilonasC , BranscombeN , et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Services Research2014;14:631.">Kourlaba 2014</a>; <a href="./references#CD013004-bbs2-0107" title="KrittayaphongR , YadeeJ , PermsuwanU . Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction. ClinicoEconomics and Outcomes Research2019;11:767-77.">Krittayaphong 2019</a>; <a href="./references#CD013004-bbs2-0119" title="PolistenaB , MaggioniA , OlivaF , SpandonaroF . Cost-effectiveness and budget impact of ivabradine in heart failure therapy (Provisional abstract). Giornale Italiano di Cardiologia2014;15:626-33.">Polistena 2014</a>; <a href="./references#CD013004-bbs2-0125" title="TaheriS , HeidariE , AivaziMA , Shams-BeyranvandM , VarmaghaniM . Cost-effectiveness analysis of Ivabradine in treatment of patients with heart failure in Iran. International Journal of Technology Assessment in Health Care2018;34(6):576–83.">Taheri 2018</a>). In contrast, <a href="./references#CD013004-bbs2-0086" title="BorerJS , DeedwaniaPC , KimJB , BoehmM . Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. American Journal of Cardiology2016;118(12):1948-53.">Borer 2016</a> and <a href="./references#CD013004-bbs2-0105" title="KansalAR , CowieMR , KielhornA , KrotnevaS , TafazzoliA , ZhengY , et al. Cost-effectiveness of ivabradine for heart failure in the United States. Journal of the American Heart Association2016;5:06.">Kansal 2016</a> aimed to estimate the budget impact of ivabradine from a US commercial payer perspective. </p> <p>All studies used a Markov model to analyse the economic data except for <a href="./references#CD013004-bbs2-0086" title="BorerJS , DeedwaniaPC , KimJB , BoehmM . Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. American Journal of Cardiology2016;118(12):1948-53.">Borer 2016</a>, who analysed a budget impact model estimated the per‐member‐per month (PMPM) impact of introducing ivabradine to existing formularies by comparing standard of care with ivabradine plus standard of care in a hypothetical one million‐member commercial and Medicare Advantage plans. </p> <p>Time horizons varied across included economic evaluations as three years (<a href="./references#CD013004-bbs2-0086" title="BorerJS , DeedwaniaPC , KimJB , BoehmM . Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. American Journal of Cardiology2016;118(12):1948-53.">Borer 2016</a>), 10 years (<a href="./references#CD013004-bbs2-0080" title="AdenaMA , HamannG , SindoneAP . Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart, Lung and Circulation2018;28(3):414-22.">Adena 2018</a>; <a href="./references#CD013004-bbs2-0105" title="KansalAR , CowieMR , KielhornA , KrotnevaS , TafazzoliA , ZhengY , et al. Cost-effectiveness of ivabradine for heart failure in the United States. Journal of the American Heart Association2016;5:06.">Kansal 2016</a>; <a href="./references#CD013004-bbs2-0125" title="TaheriS , HeidariE , AivaziMA , Shams-BeyranvandM , VarmaghaniM . Cost-effectiveness analysis of Ivabradine in treatment of patients with heart failure in Iran. International Journal of Technology Assessment in Health Care2018;34(6):576–83.">Taheri 2018</a>), and lifetime (all other studies). </p> <p>Six studies reported the cost per quality‐adjusted life‐year (QALY) (<a href="./references#CD013004-bbs2-0080" title="AdenaMA , HamannG , SindoneAP . Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart, Lung and Circulation2018;28(3):414-22.">Adena 2018</a>; <a href="./references#CD013004-bbs2-0089" title="ChangCJ , ChuPH , FannCS . Cost effectiveness of ivabradine in chronic heart failure patients with heart rate above Bpm in Taiwan. Value Health2014;17:A488.">Chang 2014</a>; <a href="./references#CD013004-bbs2-0095" title="Fernandez de BobadillaJ , GonzalezFO , Lopez de SaE , Lopez-SendonJL . Cost-effectiveness analysis of ivabradine in heart failure with reduced left ventricular ejection fraction in Spain. Value in Health2014;17:A486.">Fernandez de Bobadilla 2014</a>; <a href="./references#CD013004-bbs2-0107" title="KrittayaphongR , YadeeJ , PermsuwanU . Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction. ClinicoEconomics and Outcomes Research2019;11:767-77.">Krittayaphong 2019</a>; <a href="./references#CD013004-bbs2-0119" title="PolistenaB , MaggioniA , OlivaF , SpandonaroF . Cost-effectiveness and budget impact of ivabradine in heart failure therapy (Provisional abstract). Giornale Italiano di Cardiologia2014;15:626-33.">Polistena 2014</a>; <a href="./references#CD013004-bbs2-0125" title="TaheriS , HeidariE , AivaziMA , Shams-BeyranvandM , VarmaghaniM . Cost-effectiveness analysis of Ivabradine in treatment of patients with heart failure in Iran. International Journal of Technology Assessment in Health Care2018;34(6):576–83.">Taheri 2018</a>). Further outcome measures were very heterogenous, ranging from PMPM cost savings, <a href="./references#CD013004-bbs2-0086" title="BorerJS , DeedwaniaPC , KimJB , BoehmM . Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. American Journal of Cardiology2016;118(12):1948-53.">Borer 2016</a>, to incremental cost per additional QALY for lifetime subgrouped by heart rate, <a href="./references#CD013004-bbs2-0099" title="GriffithsA , ParachaN , DaviesA , BranscombeN , CowieMR , SculpherM . The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective (Provisional abstract). Heart2014;100(13):1031-6.">Griffiths 2014</a>, or the incremental cost‐effectiveness ratio (ICER) per QALY, <a href="./references#CD013004-bbs2-0105" title="KansalAR , CowieMR , KielhornA , KrotnevaS , TafazzoliA , ZhengY , et al. Cost-effectiveness of ivabradine for heart failure in the United States. Journal of the American Heart Association2016;5:06.">Kansal 2016</a>; <a href="./references#CD013004-bbs2-0106" title="KourlabaG , ParissisJ , KaravidasA , BeletsiA , MilonasC , BranscombeN , et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Services Research2014;14:631.">Kourlaba 2014</a>. </p> <p>All included studies concluded that ivabradine should be regarded as cost‐effective in the respective country for heart failure therapy in long‐term treatment of participants with HFrEF (see <a href="./full#CD013004-tbl-0001">summary of findings Table 1</a>). As all data were from the same study (SHIFT), differences in cost values can be explained by different cost of ivabradine, hospital costs, and currencies. GRADE was assessed as high certainty. </p> <p>Based on our findings, there is a need to verify this conclusion with independent data to raise the certainty of the evidence. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013004-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013004-sec-0095"></div> <section id="CD013004-sec-0096"> <h3 class="title" id="CD013004-sec-0096">Summary of main results</h3> <p>This review summarised 19 studies involving 19,628 participants randomly assigned to receive either ivabradine or placebo/usual care/no treatment for chronic heart failure. Most studies compared ivabradine to placebo and usual care or to usual care only. All included studies used a standard parallel‐group design. The sample size in the included studies ranged from 49 to 10,917 participants; most studies did not provide a power analysis. We noted a large gender imbalance across all studies to the detriment of female participants. Studies concentrated either on participants diagnosed with HFrEF or HFpEF; one study focused on HFmrEF, and in four studies the type of heart failure (or any other classifying determinant) was not provided. Regarding severity of heart failure, there was no clear focus in the included studies. NYHA classification included class 1 to 4 and various combinations of two or more NYHA classes, drawing a heterogenous picture of clinical presentation across studies. Regarding dosage of ivabradine, the majority of studies determined ivabradine dosage based on participant's heart rate; this ranged from 2.5 mg twice a day (often starting dose) to maximum of 15 mg twice a day. </p> <p>Due to substantial clinical heterogeneity in type of heart failure, heterogeneity regarding ivabradine treatment, and substantial heterogeneity in definition and measurement of outcome parameters, pooling of data was rarely feasible. This was worsened due to poor reporting within study reports (e.g. type of heart failure was often not mentioned). Although we contacted corresponding authors multiple times, we were not able to obtain additional information. To enable meta‐analysis, we distinguished between: 1) usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine); 2) usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine); 3) usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine); and 4) usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine). Although 19 studies met the inclusion criteria for our review, few studies contributed data to our four comparisons. </p> <p>We were able to perform two meta‐analyses focusing on participants with HFrEF and long‐term treatment of ivabradine. Regarding mortality from cardiovascular causes, we found evidence of no difference between ivabradine and placebo/usual care/no treatment. Furthermore, we found no evidence of a difference on the rate of serious adverse events in HFrEF participants randomised to receive ivabradine as a long‐term treatment compared with those randomised to placebo, usual care, or no treatment. For all other outcomes, we were not able to perform meta‐analysis. Single studies showed significant improvement in quality of life in participants with HFrEF on long‐term treatment (≥ 6 months) as well as in short‐term treatment (&lt; 6 months) with ivabradine. The serious adverse event rate was significantly worse in one single study (N = 125), whilst exercise capacity improved significantly in two single studies (N = 160) in participants with HFrEF in short‐term treatment (&lt; 6 months) with ivabradine. There was no significance in any outcome for participants with HFpEF on long‐term treatment (≥ 6 months) with ivabradine. Exercise capacity improved significantly in two single studies (N = 171) in participants with HFpEF on short‐term treatment (&lt; 6 months) with ivabradine. GRADE was assessed as high, moderate, or low due to high risk of bias, imprecision of data, or low number of participants. </p> <p>One other aspect of our systematic review warrants comment. Although we were able to include large‐scale randomised trials (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>), each of which was performed at several hundred centres in nearly 40 countries around the globe including nearly 18,000 participants, patient‐centred outcomes focusing on individual health‐related quality of life and functional outcome parameters were rarely assessed, and pooling of data on patient‐centred outcomes was not possible. </p> <p>We also performed an economic evaluation of ivabradine and included a narrative analysis of eight matching studies in this review. All studies concluded that ivabradine was cost‐effective in the respective country for heart failure therapy when provided as a long‐term treatment in participants with HFrEF. We want to point out that all analyses are based on data from the SHIFT trial reporting on long‐term treatment with ivabradine in participants with HFrEF, and all studies adapted the predeveloped Markov model to a certain population, which was purposely developed for submission to national regulatory bodies. Risk of bias in the included studies must be taken into account when interpreting the economic evaluation. </p> </section> <section id="CD013004-sec-0097"> <h3 class="title" id="CD013004-sec-0097">Overall completeness and applicability of evidence</h3> <p>Although the number of trials meeting our inclusion criteria was relatively large, most of the included studies did not report the outcomes planned for this review. Not including heart failure death as an outcome in the protocol or consequently in the analysis might be regarded by some as a limitation of this review. Nevertheless, only SHIFT studies (<a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>; <a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a>) reported this outcome. The results for such an analysis would be the same as the SHIFT studies. Significant heterogeneity in type of outcome and measurement tool prohibited pooling of data to a great extent. We believe it is of importance to highlight that this problem was of special concern for functional outcome parameters that focused on exercise capacity. Almost half of the included studies reported on exercise capacity; however, pooling was impossible due to massive inconsistency limiting the overall completeness of the available evidence. </p> <p>Regarding adherence to guideline management of chronic heart failure, we believe that this is a second factor limiting the applicability of the available evidence. Only four of the 19 included studies reported that all participants were treated adequately with beta‐blockers and ACE inhibitors (<a href="./references#CD013004-bbs2-0003" title="AdamyanK , TumasyanL , ChilingaryanA , TunyanL . Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function. European Heart Journal2015;36:666-7. ">Adamyan 2015a</a>; <a href="./references#CD013004-bbs2-0017" title="TumasyanLRL , AdamyanKG , ChilingaryanAL . Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure. European Heart Journal2012;33:808. TumasyanLRL , AdamyanKG . Efficacy of long-term ivabradine therapy on prognosis, right heart and left atrial parameters in patients with severe systolic chronic heart failure. ESC Heart Failure2016;18:110. ">Tumasyan 2016</a>; <a href="./references#CD013004-bbs2-0018" title="TumasyanLR , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction. ESC Heart Failure2017;19:413. ">Tumasyan 2017</a>; <a href="./references#CD013004-bbs2-0019" title="TumasyanLRL , AdamyanKG . Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction. European Heart Journal2018;20(S1, 5-638):256. ">Tumasyan 2018</a>). All other studies did not explicitly state that study participants were treated in accordance with current guidelines for heart failure management, nor did they state reasons why participants were not treated with beta‐blockers, ACE inhibitors, or MRA. These circumstances limit how clinicians will rate the potential of ivabradine as an adjuvant oral medication for the symptomatic treatment of chronic heart failure. </p> </section> <section id="CD013004-sec-0098"> <h3 class="title" id="CD013004-sec-0098">Quality of the evidence</h3> <p>We assessed the certainty of evidence in the included studies using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013004-bbs2-0102" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>), and by employing the GRADE approach. Six studies that matched our inclusion criteria were only available abstracts with a minimum of information on which to base judgements regarding the certainty of the evidence. Although we contacted corresponding authors multiple times, we were not able to obtain more information. GRADEpro GDT allowed us to import data from Review Manager 5 to create a ’Summary of findings’ table for two of our primary outcomes, which we were able to pool: mortality from cardiovascular causes and rate of serious adverse events (<a href="./references#CD013004-bbs2-0098" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version (accessed 9 April 2018). Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD013004-bbs2-0121" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>In participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine), we graded the certainty of the evidence for mortality from cardiovascular causes as moderate due to the high number of cases (n = 17,676) and the narrow confidence interval (0.88 to 1.11), but indirectness (male predominance). GRADE was assessed as low for quality of life due to risk of bias (blinding) and attrition bias, and as moderate due to indirectness (male predominance) for rate of serious adverse events, the data for which we were able to pool (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>; <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>). For exercise capacity, GRADE was downgraded two levels to low due to risk of bias (allocation, blinding) and imprecision (low number of participants). </p> <p>In participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine), GRADE was assessed as low for quality of life due to imprecision (low number of participants) and risk of bias (blinding), and as low for rate of serious adverse events due to imprecision (low number of participants) and publication bias (low number of studies reporting on this outcome). For exercise capacity, GRADE was downgraded two levels to low due to risk of bias (blinding) and imprecision (low number of participants). </p> <p>In participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine), GRADE was assessed as low for mortality from cardiovascular causes as well as for quality of life, rate of serious adverse events, and exercise capacity due to imprecision (low number of participants) and risk of bias (serious methodological limitations due to insufficient information on random sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data, and selective reporting). </p> <p>In participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine), GRADE was downgraded two levels to low for exercise capacity due to inconsistency (heterogeneity in parameters) and imprecision (low number of participants). </p> </section> <section id="CD013004-sec-0099"> <h3 class="title" id="CD013004-sec-0099">Potential biases in the review process</h3> <p>We undertook this systematic review in accordance with the standards of Cochrane as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013004-bbs2-0102" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We carried out a comprehensive search across relevant databases and assessed reference lists of the included studies. The process of study selection is outlined comprehensively and in full detail (<a href="#CD013004-fig-0001">Figure 1</a>). In addition, we screened reference lists of systematic reviews and contacted study authors for additional data or relevant details multiple times. We did not apply any language or date restrictions. Two review authors performed all levels of the selection process independently, and analyses were conducted by one review author and checked by a colleague. We provided reasons for the exclusion of studies from this systematic review. We described each included study in full detail and made explicit judgements on risk of bias (low, high, or unclear risk of bias). We identified no other potential sources of bias in our review process. </p> </section> <section id="CD013004-sec-0100"> <h3 class="title" id="CD013004-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>The effect sizes of treatments with ivabradine found in this article are similar to the findings of <a href="./references#CD013004-bbs2-0096" title="FoxK , KomajdaM , FordI , RobertsonM , BöhmM , BorerJS , et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal2013;34:2263-70.">Fox 2013</a> and <a href="./references#CD013004-bbs2-0126" title="ThomsenMM , LewinterC , KøberL . Varying effects of recommended treatments for heart failure with reduced ejection fraction: meta-analysis of randomized controlled trials in the ESC and ACCF/AHA guidelines. ESC Heart Failure2016;3:235–44.">Thomsen 2016</a> concerning cardiovascular death. Both reviews found no significant effect of ivabradine on cardiovascular mortality in participants with reduced ejection fraction. However, <a href="./references#CD013004-bbs2-0096" title="FoxK , KomajdaM , FordI , RobertsonM , BöhmM , BorerJS , et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal2013;34:2263-70.">Fox 2013</a> showed a significant risk reduction in heart failure hospitalisation (RR 0.87, 95% CI 0.68 to 1.10; P &lt; 0.001) and in the combined endpoint of heart failure hospitalisation and cardiovascular mortality (RR 0.87, 95% CI 0.80 to 0.94; P &lt; 0.01). A systematic review and meta‐analysis by <a href="./references#CD013004-bbs2-0100" title="HartmannC , BoschNL , MiguitaLA , TierieE , ZytinskiL , BaenaCP . The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. International Journal of Clinical Pharmacology2018;40(6):1443-53.">Hartmann 2018</a> showed that ivabradine significantly reduced heart rate, but it also showed no significant effect for all‐cause mortality, cardiovascular death, and hospitalisation due to heart failure. <a href="./references#CD013004-bbs2-0115" title="NarayananMA , ReddyYNV , BaskaranJ , DeshmukhA , BendittDG , RaveendranG . Ivabradine in the treatment of systolic heart failure - a systematic review and meta-analysis. World Journal of Cardiology2017;9(2):182-90.">Narayanan 2017</a> agreed with <a href="./references#CD013004-bbs2-0100" title="HartmannC , BoschNL , MiguitaLA , TierieE , ZytinskiL , BaenaCP . The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. International Journal of Clinical Pharmacology2018;40(6):1443-53.">Hartmann 2018</a> and further added the statement that the greater reduction in heart rate was coupled with improvement in combined endpoint of heart failure readmission and cardiovascular death. <a href="./references#CD013004-bbs2-0117" title="PeiH , MiaoW , XieW , WangW , ZhaoD , SuG , et al. Ivabradine improves cardiac function and increases exercise capacity in patients with chronic heart failure. International Heart Journal2019;60(4):899-909.">Pei 2019</a> stated that the RR of the composite endpoint cardiovascular death or worsening heart failure (RR 0.93, 95% CI 0.87 to 0.98; P = 0.01) and the RRs of admission to hospital for heart failure (RR 0.86, 95% CI 0.79 to 0.93; P &lt; 0.001) decreased significantly in participants treated with ivabradine. Furthermore, the RR of participants who died from heart failure was significantly decreased in the group treated with added ivabradine compared to the standard anti‐heart failure therapy group (RR 0.82, 95% CI 0.69 to 0.96; P = 0.02). It should be noted that the author equates cardiac death (<a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a>: "Death from myocardial infarction, heart failure, or cardiac procedures") with death from heart failure (<a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>), and also uses an incorrect number of events in the placebo group of <a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a> (n = 151 instead of n = 154) to calculate the RR. The current European Society of Cardiology guidelines recommend to consider ivabradine to reduce the risk of heart failure hospitalisation and cardiovascular death in symptomatic individuals with LVEF ≤ 35% in sinus rhythm and a resting heart rate of ≥ 70 beats per minute despite treatment with beta‐blockers, ACE‐I (or ARB), and an MRA (or ARB) (class of recommendation IIa, level of evidence B) (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). Furthermore, ivabradine should be considered in individuals of this subgroup with contraindications for beta‐blockers in combination with ACE‐I (or ARB) and an MRA (or ARB) (class of recommendation IIa, level of evidence C). Overall, recently published studies are showing similar findings as our review, however, our findings are not in line with the evidence cited by the ESC Guideline that ivabradine reduces mortality in this population (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>, p. 2151: "Ivabradine should be considered to reduce the risk of HF hospitalization and cardiovascular death in symptomatic patients with LVEF ≤ 35%, in sinus rhythm and a resting heart rate ≥70 bpm who are unable to tolerate or have contra‐indications for a beta‐blocker. Patients should also receive an ACE‐I (or ARB) and an MRA (or ARB)."). The findings of the present work may also have an impact on NICE guidance as it is also based on the assumption of a reduction of hard outcomes by ivabradine. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013004-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/urn:x-wiley:14651858:media:CD013004:CD013004-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for selection of randomised controlled trials." data-id="CD013004-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_t/tCD013004-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for selection of randomised controlled trials.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013004-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/urn:x-wiley:14651858:media:CD013004:CD013004-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for selection of economic evaluations." data-id="CD013004-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_t/tCD013004-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram for selection of economic evaluations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013004-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/urn:x-wiley:14651858:media:CD013004:CD013004-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013004-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_t/tCD013004-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013004-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/urn:x-wiley:14651858:media:CD013004:CD013004-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013004-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_t/tCD013004-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013004-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/urn:x-wiley:14651858:media:CD013004:CD013004-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine), Outcome 1: Mortality from cardiovascular causes (follow‐up range 19 months to 23 months)" data-id="CD013004-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_t/tCD013004-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine), Outcome 1: Mortality from cardiovascular causes (follow‐up range 19 months to 23 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/references#CD013004-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013004-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/urn:x-wiley:14651858:media:CD013004:CD013004-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine), Outcome 2: Rate of serious adverse events" data-id="CD013004-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_t/tCD013004-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine), Outcome 2: Rate of serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/references#CD013004-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/media/CDSR/CD013004/image_n/nCD013004-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013004-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)<br/><b>Setting:</b> hospital or outpatient care<br/><b>Intervention:</b> long‐term treatment (≥ 6 months) with ivabradine<br/><b>Comparison:</b> placebo, usual care, or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality from cardiovascular causes (follow‐up range 19 to 23 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000 (93 to 117)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/>(0.88 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,676<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of no difference as the effect is close to 1 and the CI is narrow.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>: Treatment with ivabradine improved Kansas City Cardiomyopathy Questionnaire (KCCQ) by 1.8 (95% CI 0.30 to 3.24) for clinical summary score (CSS) and by 2.4 (95% CI 0.91 to 3.85) for overall summary score (OSS) (placebo‐corrected, P = 0.018 and P &lt; 0.001, respectively). </p> <p><a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>: Significant improvement (P = 0.004, no further details available) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2102</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first hospitalisation for heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of days spent in hospital due to heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>321 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000<br/>(296 to 321) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/>(0.92 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,399<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 additional RCTs (207 participants) could not be pooled.</p> <p><a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>: Author reported that no significant adverse effects on ivabradine therapy were noted at the end of 6 months; no further details are provided. </p> <p><a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a>: Author reported that the addition of ivabradine to standard treatment promoted less fatal cardiovascular events; no further details are provided. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise capacity</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>: No significant improvement for ivabradine group in exercise duration (320 ± 130.6 s vs 311.79 ± 103.60 s) (P = 0.663) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Economic costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>All data are based on the SHIFT trial by <a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a>: </p> <p><a href="./references#CD013004-bbs2-0080" title="AdenaMA , HamannG , SindoneAP . Cost-effectiveness of ivabradine in the treatment of chronic heart failure. Heart, Lung and Circulation2018;28(3):414-22.">Adena 2018</a>: Ivabradine is likely to be cost‐effective in Australia (cost per QALY = AUS 14,905). </p> <p><a href="./references#CD013004-bbs2-0086" title="BorerJS , DeedwaniaPC , KimJB , BoehmM . Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. American Journal of Cardiology2016;118(12):1948-53.">Borer 2016</a>: Ivabradine led to lower average annual treatment costs in the US (PMPM cost savings year 3: USD 0.04). </p> <p><a href="./references#CD013004-bbs2-0089" title="ChangCJ , ChuPH , FannCS . Cost effectiveness of ivabradine in chronic heart failure patients with heart rate above Bpm in Taiwan. Value Health2014;17:A488.">Chang 2014</a>: Ivabradine is likely to be cost‐effective in Taiwan (cost per QALY: GBP 14,832). </p> <p><a href="./references#CD013004-bbs2-0095" title="Fernandez de BobadillaJ , GonzalezFO , Lopez de SaE , Lopez-SendonJL . Cost-effectiveness analysis of ivabradine in heart failure with reduced left ventricular ejection fraction in Spain. Value in Health2014;17:A486.">Fernandez de Bobadilla 2014</a>: Ivabradine is cost‐effective in Spain (cost per QALY: EUR 17,488/cost per LYG: EUR 13,044). </p> <p><a href="./references#CD013004-bbs2-0099" title="GriffithsA , ParachaN , DaviesA , BranscombeN , CowieMR , SculpherM . The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective (Provisional abstract). Heart2014;100(13):1031-6.">Griffiths 2014</a>: Ivabradine is likely to be cost‐effective in the UK (cost per QALY: GBP 8498 (≥ 75 bpm)/GBP 13,764 (≥ 70 bpm). </p> <p><a href="./references#CD013004-bbs2-0105" title="KansalAR , CowieMR , KielhornA , KrotnevaS , TafazzoliA , ZhengY , et al. Cost-effectiveness of ivabradine for heart failure in the United States. Journal of the American Heart Association2016;5:06.">Kansal 2016</a>: Ivabradine is associated with cost savings in the USA (cost saving over 10‐year time horizon: USD 8594/QALY: 0.24/ICER per QALY: USD 24,920). </p> <p><a href="./references#CD013004-bbs2-0106" title="KourlabaG , ParissisJ , KaravidasA , BeletsiA , MilonasC , BranscombeN , et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Services Research2014;14:631.">Kourlaba 2014</a>: Ivabradine is a cost‐effective option in Greece (cumulative lifetime total cost per patient EUR 8665 vs EUR 5837/ICER per QALY: EUR 9986). </p> <p><a href="./references#CD013004-bbs2-0107" title="KrittayaphongR , YadeeJ , PermsuwanU . Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction. ClinicoEconomics and Outcomes Research2019;11:767-77.">Krittayaphong 2019</a>: The addition of ivabradine to standard treatment is a cost‐effective treatment strategy in HFrEF patients in Thailand with a heart rate ≥ 77 bpm (USD 6515.16/QALY). </p> <p><a href="./references#CD013004-bbs2-0119" title="PolistenaB , MaggioniA , OlivaF , SpandonaroF . Cost-effectiveness and budget impact of ivabradine in heart failure therapy (Provisional abstract). Giornale Italiano di Cardiologia2014;15:626-33.">Polistena 2014</a>: Results show social acceptability of ivabradine in Italy (cost per QALY: EUR 17,435/cost per LYG: EUR 15,557/HOS costs avoided: EUR 3420). </p> <p><a href="./references#CD013004-bbs2-0125" title="TaheriS , HeidariE , AivaziMA , Shams-BeyranvandM , VarmaghaniM . Cost-effectiveness analysis of Ivabradine in treatment of patients with heart failure in Iran. International Journal of Technology Assessment in Health Care2018;34(6):576–83.">Taheri 2018</a>: From an Iranian healthcare system, the analysis indicates that the clinical benefit of ivabradine can be achieved at a reasonable cost in eligible hear failure patients (cost per QALY: USD 5437). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6558</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the </p> <p><b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>bpm:</b> beats per minute; <b>CI:</b> confidence interval; <b>HFrEF:</b> heart failure with reduced ejection fraction; <b>HOS:</b> hospitalization; <b>ICER:</b> Incremental cost‐effectiveness ratio; <b>LYG:</b> life years gained;<b>PMPM:</b> per member per month; <b>QALY:</b> quality‐adjusted life year; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to indirectness (male predominance).<br/><sup>2</sup>Downgraded by one level due to risk of bias (allocation, blinding).<br/><sup>3</sup>Downgraded by one level due to imprecision (low number of participants).<br/><sup>4</sup>Downgraded by one level due to attrition bias (only around 30% of the overall trial participants contributed data). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013004-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)<br/><b>Setting:</b> hospital or outpatient care<br/><b>Intervention:</b> short‐term treatment (&lt; 6 months) with ivabradine<br/><b>Comparison:</b> placebo, usual care, or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality from cardiovascular causes (follow‐up range 19 to 23 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>: Minnesota Living with Heart Failure Questionnaire </p> <p>Significant improvement for ivabradine at 3 months vs baseline (37.5 + 1.9 vs 30.9 + 2.3) (P &lt; 0.001); no significant difference for control at 3 months vs baseline (31.2 + 2.6 vs 30.6 + 2.1) (P = n.s.) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first hospitalisation for heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of days spent in hospital due to heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a>: Significant worsening of adverse events (heart failure, phosphenes, diarrhoea, nasopharyngitis): 54.8% (2.5 mg ivabradine); 64.3% (5 mg ivabradine) vs 29.3% (control) (P = 0.004) </p> <p><a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>: Noticeable side effects requiring the withdrawal of drugs were not observed. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>270</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>LOW<sup>1, 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise capacity</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>: Significant improvement for ivabradine group in exercise duration at 3 months (497 s vs 328 s) (P = 0.024) </p> <p><a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>: Significant improvement for ivabradine group in exercise duration at 90 days (495 ± 147 s vs 416 ± 128 s) (P &lt; 0.05) </p> <p><a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a>: Significant improvement for ivabradine group in exercise duration at 3 months (28.2 ± 3.5 min vs 14.8 ± 2.5 min) (P &lt; 0.001) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Economic costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HFrEF:</b> heart failure with reduced ejection fraction;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision (low number of participants).<br/><sup>2</sup>Downgraded by one level due to risk of bias (blinding).<br/><sup>3</sup>Downgraded by one level due to publication bias (low number of studies reporting on this outcome). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (short‐term treatment (&lt; 6 months) with ivabradine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013004-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with a diagnosis of chronic heart failure with a preserved ejection fraction (HFpEF)<br/><b>Setting:</b> hospital or outpatient care<br/><b>Intervention:</b> long‐term treatment (≥ 6 months) with ivabradine<br/><b>Comparison:</b> placebo, usual care, or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care with ivabradine compared to placebo, usual care, or no treatment in patients with HFpEF (long‐term treatment (≥ 6 months) with ivabradine)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality from cardiovascular causes</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>: 1 death from cardiovascular cause occurred in the ivabradine group (ischaemic stroke); no deaths occurred in the control group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a> </p> <p>No significant improvement (no further details available)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first hospitalisation for heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of days spent in hospital due to heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>: No significant difference in improvement (35.1% vs 25.0%) (P = 0.191) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise capacity</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a>: No significant improvement for ivabradine group in 6‐minute walk test (change of last postbaseline value from baseline: +0.0 m vs +11.0 m) (P = 0.882) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Economic costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HFpEF:</b> heart failure with a preserved ejection fraction; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for imprecision (low number of participants).<br/><sup>2</sup>Downgraded by one level due to risk of bias (serious methodological limitations due to insufficient information on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (long‐term treatment (≥ 6 months) with ivabradine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013004-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults (≥ 18 years of age) with a diagnosis of chronic heart failure with a preserved ejection fraction (HFpEF)<br/><b>Setting:</b> hospital or outpatient care<br/><b>Intervention:</b> short‐term treatment (&lt; 6 months) with ivabradine<br/><b>Comparison:</b> placebo, usual care, or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality from cardiovascular causes (follow‐up range 19 to 23 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first hospitalisation for heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of days spent in hospital due to heart failure during follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exercise capacity</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>: Significant improvement for ivabradine in exercise duration (baseline: 5.4 ± 2.1 min vs follow‐up at month 3: 6.9 ± 2.9 min) (P &lt; 0.05). No data for placebo group. </p> <p><a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a>: Significant improvement for ivabradine group (baseline: 4.2 ± 1.8 metabolic equivalents vs follow‐up at day 7: 5.7 ± 1.9 metabolic equivalents) (P = 0.001). "No change in the control subjects." </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Economic costs</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in studies that met the inclusion criteria for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HFpEF:</b> heart failure with a preserved ejection fraction; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to inconsistency (heterogeneity in parameters).<br/><sup>2</sup>Downgraded by one level due to imprecision (low number of participants). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFpEF (short‐term treatment (&lt; 6 months) with ivabradine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013004-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">New York Heart Association (NYHA) classification</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Class</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other descriptor</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms with ordinary activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild symptoms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>III</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms with less than ordinary<br/>activity </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate symptoms</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms at rest or with any minimal<br/>activity </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe symptoms</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">New York Heart Association (NYHA) classification</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013004-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Study characteristics of studies with HFrEF</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reference</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of centres</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ivabradine</b> </p> <p><b>[n]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo/SC</b> </p> <p><b>[n]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dosage</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration IP</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Timing outcomes</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ejection fraction [%]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Guideline adherence***</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="10" rowspan="1" scope="col" valign="bottom"> <p><b>Short‐term treatment (&lt; 6 months) with ivabradine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0001" title="AbdelHY . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. ESC Heart Failure2011;10:107. ">Abdel 2011</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 0, 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EF &lt; 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0002" title="AdamyanKG , ChilingarianAL , AstvacatryanAV . Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers. Circulation2008;118:341-2. ">Adamyan 2008</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, 30, 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EF &lt; 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with intolerance to BB were included; ACE/ARB and MRA were given.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0004" title="BansalS , ChaudharyM . Importance of serum sodium in ischemic heart failure with systolic dysfunction. European Journal of Heart Failure2019;21(Suppl S1):5-592. ">Bansal 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0011" title="SarulloFM , FazioG , PuccioD , FasulloS , PaternaS , NovoS , et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(4):349-55. SarulloFM , GuttillaD , FazioG , PaternaS , Di PasqualeP , CastelloA . Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure. European Heart Journal2009;30:866. ">Sarullo 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 0, 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≤ 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (60.1%); ACE inhibitor (85%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0015" title="TsutsuiH , MomomuraS . Heart rate control with If inhibitor, ivabradine, in Japanese patients with chronic heart failure – a randomized, double-blind, placebo-controlled phase II study. Circulation Journal2016;80:668-76. ">Tsutsui 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 to 7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 0, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≤ 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (92.9%); ACE inhibitor (45.8%); ARB (26.8%); ACE inhibitor or ARB (70.6%); MRA (55.1%) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Long‐term treatment (</b> ≥<b>6 months) with ivabradine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0005" title="ChaudhariM , ChakrabortyP , PathakS , IsserH , BansalS . Effects of ivabradine on left ventricular function in patients with ischemic heart failure. Indian Heart Journal2014;66:83-4. ">Chaudhari 2014</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 0, 6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF &lt; 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0007" title="Beautiful Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology2008;110:271-82. FoxK , FordI , StegPG , TenderaM , FerrariR , on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet2008;372(9641):807-16. FoxK , FordI , StegPG , TenderaM , RobertsonM , FerrariR , et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet2008;372(9641):817-21. NCT00143507. The BEAUTIFUL Study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction. clinicaltrials.gov/ct2/show/NCT00143507 (first received 21 November 2018). TenderaM , TalajicM , RobertsonM , TardifJC , FerrariR , FordI , et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter substudy). American Journal of Cardiology2011;107(6):805-11. ">Fox 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>781</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5479</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5438</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>~M 19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, W 2, M 1, 3, 6, 12, 18, 24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF &lt; 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (83.5%); ACE inhibitor or ARB or both (89.5%); MRA (29.5%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0010" title="PotapenkoAV , AbdulazizovO , DiachukLI , KiiakbaevGK , KobalavaZ , MoiseevVS . Efficacy of Ivabradine in combined treatment of patients with postinfarction systolic chronic cardiac failure. Terapevticheskii Arkhiv2011;83(12):19-26. ">Potapenko 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day**</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y 3, 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Y 3, 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF &lt; 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (85.7%); ACE inhibitor (96%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0012" title="SisakianHH , SargsyanT , KhachatryanA . Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure. Acta Cardiologica2016;71(3):317-22. ">Sisakian 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>SC </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 mg/5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, 14, 28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF &lt; 40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (79.7%); ACE inhibitor and/or ARB (85.2%); MRA (25.5%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0013" title="BöhmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. European Journal of Heart Failure2018;20:373–81. BocchiEA , GuimaraesG . Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. Journal of the American College of Cardiology2017;69(11):922. BocchiEA , RassiS , Guimarães GV and Argentina, Chile, and Brazil SHIFT Investigators. Efficacy and safety profile of ivabradine in heart failure due to chagaś heart disease: a post-hoc analysis of the SHIFT trial. ESC Heart Failure2018;5:249–56. BoehmM , BorerJ , FordI , Gonzalez-JuanateyJR , KomajdaM , Lopez-SendonJ , et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology2013;102:11-22. BoehmM , BorerJS , CammJ , FordI , LloydSM , KomajdaM , et al. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. ESC Heart Failure2015;17:518-26. BoehmM , BorerJS , FordI , KomajdaM , RobertsonM , TavazziL , et al. Effect of comorbidities and risk factors on outcomes and ivabradine's effects in patients with chronic systolic heart failure in the SHIFT trial. Journal of Cardiac Failure2015;21(8S):S46. BoehmM , BorerJS , FordI , LainscakM , KomajdaM , RobertsonM , et al. Effect of comorbidities on outcomes and ivabradine effects in patients with chronic systolic heart failure in the SHIFT trial. ESC Heart Failure2015;17 Suppl 1:266. BoehmM , KomajdaM , BorerJS , FordI , MaackC , TavazziL , et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. ESC Heart Failure2018;20:373-81. BoehmM , LloydSM , FordI , BorerJS , EwenS , LaufsU , et al. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. ESC Heart Failure2016;18:672-83. BoehmM , RobertsonM , BorerJ , FordI , KomajdaM , MahfoudF , et al. Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the systolic heart failure treatment with the If inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association2016;5(2):e002160. BoehmM , RobertsonM , FordI , BorerJS , KomajdaM , KindermannI , et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). American Journal of Cardiology2015;116(12):1890-7. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , Dubost-BramaA , et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet2010;376:886-94. BoehmM , SwedbergK , KomajdaM , BorerJS , FordI , ReilJ , et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85. BoehmM , SwedbergK , KomajdaM , TavazziL , BorerJS , MoyneA , et al. Ivabradine effect on outcomes in patients with systolic heart failure according to the duration of their disease: analysis from SHIFT. ESC Heart Failure2017;19(Suppl S1):225. BorerJ , BoehmM , FordI , KomajdaM , TavazziL , Lopez-SendonJ , et al. Effect of therapeutic heart rate slowing on recurring hospitalizations for worsening heart failure in CAD patients. Cardiology2013;126:11. BorerJ , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Heart rate slowing with ivabradine in patients with heart failure who also have angina pectoris. Cardiology2015;132(S1):11. BorerJ , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Safety of continuing ivabradine treatment during hospitalization for worsening of heart failure in the SHIFT study. Circulation2015;132(Suppl 3):18395. BorerJS , BoehmM , FordI , KomajdaM , SwedbergK , TavazziL . Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. JACC: Heart Failure2015;3(3):267-72. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SendonJL , et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal2012;33:2813-20. BorerJS , BoehmM , FordI , KomajdaM , TavazziL , SwedbergK . Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. ESC Heart Failure2013;12(Suppl 1):S151. BorerJS , BoehmM , FordI , RobertsonM , KomajdaM , TavazziL , et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). American Journal of Cardiology2014;113(3):497-503. BorerJS , KomajdaM , FordI , TavazziL , DominjonF , MayaJ , et al. Effects of heart rate reduction in black patients from the SHIFT (systolic heart failure treatment with the if inhibitor ivabradine trial) study. Journal of Cardiac Failure2015;21(8):S45. BorerJS , SwedbergK , KomajdaM , BoehmM , TavazziL , FordL . Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. JACC2015;65(10 Suppl):A791. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Beta blocker dosage and use over time in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT) study. JACC2015;65(10S):A872. BorerJS , SwedbergK , KomajdaM , FordI , TavazziL , BoehmM , et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris. Cardiology2017;136:138-44. BouabdallaouiN , O’MearaE , BernierV , KomajdaM , SwedbergK , TavazziL , et al. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. ESC Heart Failure2019;6:1199–207. CammJ , TalajicM , KomajdaM , BohmM , BorerJ , FordI , et al. Cardiac safety of the sino atrial node f channel blocker ivabradine in chronic heart failure: an ECG-holter sub-study. Journal of Cardiac Failure2014;20(8S):S38. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl_1):ehx501.246. ClelandJG , RobertsonM , FordI , MareevY , BorerJ , KomajdaM , et al. Effect of ivabradine on mortality in patients with heart failure and a reduced left ventricular ejection fraction not receiving a beta-blocker: an analysis from SHIFT. European Heart Journal2017;38(Suppl 1):42. DietlA , SimonI , DannerE , MorbachC , StoerkS , KomajdaM , et al. Ivabradine improves systolic ejection time in heart failure with reduced ejection fraction by heart rate-dependent and -independent mechanisms - results from the SHIFT echocardiography substudy. European Journal of Heart Failure2019;21(Suppl 1):5. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , MoyneA , et al. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18:1182-9. KomajdaM , TavazziL , SwedbergK , BoehmM , BorerJS , RobertsonM , et al. Clinical profiles and outcomes of patients with chronic heart failure and diabetes: efficacy and safety of ivabradine. A SHIFT study analysis. ESC Heart Failure2014;16:42. KomajdaMM , TavazziL , SwedbergK , BoehmM , BorerJS , FordI . Reduction in early recurrent hospitalisations after discharge for worsening heart failure with ivabradine: a post-hoc analysis of SHIFT. ESC Heart Failure2016;18(S1):293. KrotnevaS , KansalA , ZhengY , PatelH , KielhornA , BöhmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the Systolic Heart failure treatment with the IF inhibitor ivabradine Trial (SHIFT). Circulation2016;134:16738. KrotnevaS , KansalAR , IshakKJ , KielhornA , PatelH , BorerJS . Effect of ivabradine on readmission: a post-hoc bayesian analysis of 30-day readmission rates in the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Journal of Cardiac Failure2015;21(8):S107. KrotnevaS , KansalAR , ZhengY , PatelHK , KielhornA , BoehmM , et al. Estimation of decrements of utility associated with hospitalizations in a population with heart failure from the systolic heart failure treatment with the if inhibitor ivabradine trial (SHIFT). Circulation2018;134:A16738. KrumH , SindoneA . Significant reduction in all-cause mortality with ivabradine in chronic heart failure patients with baseline heart rate &gt;= 77 BPM: subgroup analysis of SHIFT. Heart, Lung and Circulation2013;22:S87-8. LainscakM , TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJ , et al. Clinical profile, outcomes, and ivabradine effects in patients with chronic obstructive pulmonary disease and chronic heart failure: The SHIFT trial analysis. European Respiratory Journal2013;42:P1860. NCT02441218. Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (SHIFT). clinicaltrials.gov/ct2/show/NCT02441218 (first received 21 November 2018). NguyenL , SquaraP , AmourJ , CholleyB . Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial. Archives of Cardiovascular Diseases2018;10(S1):41. RamiresFJ , MartinezF , GómezEA , DemacqC , GimpelewiczCR , RouleauJL . Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas’ cardiomyopathy. ESC Heart Failure2018;5:1069-71. ReilJC , TardifJC , FordI , LloydSM , O'MearaE , KomajdaM , et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. JACC2013;62(21):1977-85. SwedbergK , KomajdaM , BoehmM , BorerJ , RobertsonM , TavazziL , et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. JACC2012;59(22):1938-45. SwedbergK , KomajdaM , BohmM , BorerJS , FordI , TavazziL . Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). ESC Heart Failure2010;12(1):75-81. TardifJC , O'MearaE , KomajdaM , BoehmM , BorerJS , FordI , et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. European Heart Journal2011;32(20):2507-15. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. International Journal of Cardiology2013;170(2):182-8. TavazziL , SwedbergK , KomajdaM , BoehmM , BorerJS , LainscakM , et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. ESC Heart Failure2013;15(11):1296-303. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. ESC Heart Failure2014;16(4):426-34. VoorsA , VeldhuisenD , RobertsonM , FordI , BorerJ , BoehmM , et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. European Heart Journal2013;34(Suppl 1):162-3. ">Swedberg 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>677</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3268</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3290</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, M 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≤ 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (89.5%); ACE inhibitor (78.5%); MRA (60.0%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0016" title="JPRN‐JapicCTI‐153007. ONO-1162 phase 3 study. rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-153007 (first registered 1 September 2015). TsutsuiH , MomomuraS , YamashinaA , ShimokawaH , KiharaY , SaitoY , et al. Efficacy and safety of ivabradine in Japanese patients with chronic heart failure - J-SHIFT study. Circulation Journal2019;83:2049-60. ">Tsutsui 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 to 7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>every 2 M</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≤ 35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACE inhibitor (48.9%); ARB (20.1%); ACE inhibitor and/or ARB (68.5%); MRA (77.6%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>∑ 9393</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>∑ 9337</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>*Reported only as abstract.<br/>**Initial dose 5 mg twice a day; after 2 weeks with a heart rate of 60/min or higher: 7.5 mg twice a day; if heart rate dropped below 50/min or other clinical symptoms of bradycardia: again 5 mg twice a day; if symptoms did not improve: ivabradine treatment stopped.<br/>***According to the European Society of Cardiology (ESC) Clinical Practice Guideline on Acute and Chronic Heart Failure (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). </p> <p>Abbreviations: ns = not specified; Y = year; M = month; W = week; D = day; ACE inhibitor = angiotensin‐converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BB = beta‐blockers; EF = ejection fraction; HFrEF = heart failure with reduced ejection fraction; IP = interventional product; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; SC = standard care </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Study characteristics of studies with HFrEF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013004-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study characteristics of studies with HFpEF</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Reference</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of centres</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ivabradine</b> </p> <p><b>[n]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo/SC</b> </p> <p><b>[n]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Dosage</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration IP</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Timing outcomes</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ejection fraction [%]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Guideline adherence***</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Short‐term treatment (&lt; 6 months) with ivabradine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0006" title="De Masi De LucaG , AccogliM , PalmisanoP , De Masi De LucaA , PalumboF , GiuncatoG , et al. Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation2013;A16580:128. De Masi De LucaG , CapulziniL , AccogliM , De Masi De LucaA , MangiaR , PalumboF , et al. Ivabradine and diastolic heart failure. JACC2012;59(13):E1009. ">De Masi De Luca 2013</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 0, 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EF ≥ 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0009" title="KosmalaW , HollandD , RojekA , WrightL , Przewlocka-KosmalaM , MarwickT . Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. JACC2013;62:1330-8. ">Kosmala 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine<br/>Placebo </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>W 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>D 0, 7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≥ 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ns</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Long‐term treatment (</b> ≥<b>6 months) with ivabradine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013004-bbs2-0008" title="EUCTR2012-002742-20-HU. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction an 8-month, randomised double-blind, placebo controlled, international, multicentre study - EDIFY. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002742-20 (first received 21 November 2018). KomajdaM , IsnardR , Cohen‐SolalA , MetraM , PieskeB , PonikowskiP , et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. ESC Heart Failure2017;19:1495-503. ">Komajda 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ivabradine</p> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 mg/5 mg/7.5 mg twice a day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>M 0, 2, 4, 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LVEF ≥ 45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BB (74.3%); ACE inhibitor or ARB (87.2%); MRA (29.3%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>∑ 178</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>∑ 173</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>*Reported only as abstract.<br/>**Initial dose 5 mg twice a day; after 2 weeks with a heart rate of 60/min or higher: 7.5 mg twice a day; if heart rate dropped below 50/min or other clinical symptoms of bradycardia: again 5 mg twice a day; if symptoms did not improve: ivabradine treatment stopped.<br/>***According to the European Society of Cardiology (ESC) Clinical Practice Guideline on Acute and Chronic Heart Failure (<a href="./references#CD013004-bbs2-0120" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Journal of Heart Failure2016;37(27):2129-200.">Ponikowski 2016</a>). </p> <p>Abbreviations: ns = not specified; M = month; W = week; D = day; ACE inhibitor = angiotensin‐converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BB = beta‐blockers; EF = ejection fraction; IP = interventional prodcut; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; SC = standard care </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study characteristics of studies with HFpEF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/full#CD013004-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013004-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mortality from cardiovascular causes (follow‐up range 19 months to 23 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Rate of serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.92, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Usual care with ivabradine compared to placebo, usual care, or no treatment in participants with HFrEF (long‐term treatment (≥ 6 months) with ivabradine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013004.pub2/references#CD013004-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013004.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013004-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013004-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013004-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013004-note-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013004-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013004-note-0011">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD013004-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013004-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013004\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013004\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013004\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013004\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013004\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6XSHdtL3&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013004.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013004.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013004.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013004.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013004.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720344357"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013004.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720344361"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013004.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfedded229377',t:'MTc0MDcyMDM0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 